=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d l3
L3 HAS NO ANSWERS
L3 STR



G1 Hy,Ak,O,CN

Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 15:36:34 ON 30 JAN 2006)

FILE 'REGISTRY' ENTERED AT 15:37:12 ON 30 JAN 2006
L1 STRUCTURE UPLOADED
L2 50 S L1
L3 STRUCTURE UPLOADED
L4 19 S L3
L5 817 S L3 FUL
L6 774 S L5 AND CAPLUS/LC
L7 43 S L5 NOT L6
L8 2 S L5 AND REF.CAPLUS>10

FILE 'CAPLUS' ENTERED AT 15:42:32 ON 30 JAN 2006
L9 195 S L5

1/30/06

SRNT

L7 ANSWER 26 OF 43 REGISTRY COPYRIGHT 2006 ACS on STN
RN 412309-17-2 REGISTRY
ED Entered STN: 08 May 2002
CN Oxazole, 4-(4-methylphenyl)-5-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C16 H13 N O
SR Reaction Database



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 2 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:146569 CAPLUS
DOCUMENT NUMBER: 128:192645
TITLE: Preparation of [(alkylsulfonyl)phenyl]oxazoles and analogs as cyclooxygenase II inhibitors
INVENTOR(S): Norman, Bryan H.; Lee, Len F.; Masferrer, Jaime L.; Talley, John J.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: U.S., 51 pp., Cont.-in-part of U.S. 5,380,738.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5719163	A	19980217	US 1995-535227	19951027
US 5380738	A	19950110	US 1993-65730	19930521
WO 9427980	A1	19941208	WO 1994-US5395	19940519

W: AT, AU, BB, BG, BR, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KR, LU, NL, NO, NZ, PL, PT, RO
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, NL, PT, SE

PRIORITY APPLN. INFO.: US 1993-65730 A2 19930521
WO 1994-US5395 W 19940519
OTHER SOURCE(S): MARPAT 128:192645
GI



II

AB R2O2SZ2Z1R1 [I; R1 = (un)substituted cycloalk(en)yl, -(hetero)aryl; R2 = NH2 or (halo)alkyl; Z1 = 2-(un)substituted oxazolediyl; Z2 = 1,4-phenylene] were prepared Thus, 4-FC6H4COCH2C6H4(SMe)-4 was treated with NaH/Me3CMe2SiCl and the silyl enol ether product treated with 3-ClC6H4CO3H to give 4-FC6H4CH(OSiMe2CMe3)COC6H4(SMe)-4 which was deprotected and the product O-acylated by PhCH2CH2COCl to give, after cyclization, title compound II. Data for biol. activity of I were given.

IT **163303-61-5P 163303-62-6P 163303-63-7P**
163303-64-8P 163303-65-9P 163303-66-0P
163303-67-1P 163303-68-2P 163303-69-3P
163303-70-6P 163303-71-7P 163303-72-8P
163303-80-8P 163303-81-9P 163303-82-0P
163303-83-1P 163303-84-2P 163303-85-3P

163303-86-4P 163303-87-5P 163303-88-6P
163303-89-7P 163303-90-0P 163303-91-1P
163304-37-8P 163304-38-9P 163304-39-0P
163304-40-3P 163304-41-4P 163304-42-5P
163304-43-6P 163304-44-7P 163304-45-8P
163304-46-9P 163304-47-0P 163304-48-1P
203517-59-3P 203517-60-6P 203517-61-7P
203517-62-8P 203517-63-9P 203517-64-0P
203517-65-1P 203517-66-2P 203517-67-3P
203517-68-4P 203517-69-5P 203517-70-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [(alkylsulfonyl)phenyl]oxazoles and analogs as cyclooxygenase II inhibitors)

RN 163303-61-5 CAPLUS
CN Benzenesulfonamide, 4-[4-(4-methoxyphenyl)-2-(phenylmethyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 163303-62-6 CAPLUS
CN Benzenesulfonamide, 4-[4-(3,4-dimethoxyphenyl)-2-(phenylmethyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 163303-63-7 CAPLUS
CN Benzenesulfonamide, 4-[4-(4-methylphenyl)-2-(phenylmethyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 163303-64-8 CAPLUS
CN Benzenesulfonamide, 4-[4-(3,4-dimethylphenyl)-2-(phenylmethyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 163303-65-9 CAPLUS
CN Benzenesulfonamide, 4-[4-(3-chloro-4-methylphenyl)-2-(phenylmethyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 163303-66-0 CAPLUS
CN Benzenesulfonamide, 4-[4-(4-chloro-3-methylphenyl)-2-(phenylmethyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 163303-67-1 CAPLUS
CN Benzenesulfonamide, 4-[4-(3-chloro-4-methoxyphenyl)-2-(phenylmethyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 163303-68-2 CAPLUS
CN Benzenesulfonamide, 4-[4-(4-chloro-3-methoxyphenyl)-2-(phenylmethyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 163303-69-3 CAPLUS
CN Benzenesulfonamide, 4-[4-(3,5-dichloro-4-methoxyphenyl)-2-(phenylmethyl)-5-

oxazolyl]- (9CI) (CA INDEX NAME)



RN 163303-70-6 CAPLUS
CN Benzenesulfonamide, 4-[4-(3-fluoro-4-methylphenyl)-2-(phenylmethyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 163303-71-7 CAPLUS
CN Benzenesulfonamide, 4-[4-(4-fluoro-3-methylphenyl)-2-(phenylmethyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 163303-72-8 CAPLUS

CN Benzenesulfonamide, 4-[4-(3-fluoro-4-methoxyphenyl)-2-(phenylmethyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 163303-80-8 CAPLUS
CN Oxazole, 5-(4-methoxyphenyl)-4-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163303-81-9 CAPLUS
CN Oxazole, 5-(3,4-dimethoxyphenyl)-4-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163303-82-0 CAPLUS
CN Oxazole, 5-(4-methylphenyl)-4-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163303-83-1 CAPLUS
CN Oxazole, 5-(3,4-dimethylphenyl)-4-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163303-84-2 CAPLUS
CN Oxazole, 5-(3-chloro-4-methylphenyl)-4-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163303-85-3 CAPLUS
CN Oxazole, 5-(4-chloro-3-methylphenyl)-4-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163303-86-4 CAPLUS
CN Oxazole, 5-(3-chloro-4-methoxyphenyl)-4-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163303-87-5 CAPLUS
CN Oxazole, 5-(4-chloro-3-methoxyphenyl)-4-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163303-88-6 CAPLUS
CN Oxazole, 5-(3,5-dichloro-4-methoxyphenyl)-4-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163303-89-7 CAPLUS
CN Oxazole, 5-(3-fluoro-4-methylphenyl)-4-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163303-90-0 CAPLUS
CN Oxazole, 5-(4-fluoro-3-methylphenyl)-4-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163303-91-1 CAPLUS
CN Oxazole, 5-(3-fluoro-4-methoxyphenyl)-4-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163304-37-8 CAPLUS
CN Oxazole, 4-(4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163304-38-9 CAPLUS
CN Oxazole, 4-(3,4-dimethoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163304-39-0 CAPLUS
CN Oxazole, 4-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163304-40-3 CAPLUS
CN Oxazole, 4-(3,4-dimethylphenyl)-5-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163304-41-4 CAPLUS
CN Oxazole, 4-(3-chloro-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163304-42-5 CAPLUS
CN Oxazole, 4-(4-chloro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163304-43-6 CAPLUS
CN Oxazole, 4-(3-chloro-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163304-44-7 CAPLUS
CN Oxazole, 4-(4-chloro-3-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163304-45-8 CAPLUS
CN Oxazole, 4-(3,5-dichloro-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163304-46-9 CAPLUS
CN Oxazole, 4-(3-fluoro-4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163304-47-0 CAPLUS
CN Oxazole, 4-(4-fluoro-3-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 163304-48-1 CAPLUS
CN Oxazole, 4-(3-fluoro-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-2-

(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 203517-59-3 CAPLUS
CN Benzenesulfonamide, 4-[5-(4-methoxyphenyl)-2-(phenylmethyl)-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 203517-60-6 CAPLUS
CN Benzenesulfonamide, 4-[5-(3,4-dimethoxyphenyl)-2-(phenylmethyl)-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 203517-61-7 CAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-2-(phenylmethyl)-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 203517-62-8 CAPLUS
CN Benzenesulfonamide, 4-[5-(3,4-dimethylphenyl)-2-(phenylmethyl)-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 203517-63-9 CAPLUS
CN Benzenesulfonamide, 4-[5-(3-chloro-4-methylphenyl)-2-(phenylmethyl)-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 203517-64-0 CAPLUS
CN Benzenesulfonamide, 4-[5-(4-chloro-3-methylphenyl)-2-(phenylmethyl)-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 203517-65-1 CAPLUS
CN Benzenesulfonamide, 4-[5-(3-chloro-4-methoxyphenyl)-2-(phenylmethyl)-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 203517-66-2 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-chloro-3-methoxyphenyl)-2-(phenylmethyl)-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 203517-67-3 CAPLUS

CN Benzenesulfonamide, 4-[5-(3,5-dichloro-4-methoxyphenyl)-2-(phenylmethyl)-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 203517-68-4 CAPLUS

CN Benzenesulfonamide, 4-[5-(3-fluoro-4-methylphenyl)-2-(phenylmethyl)-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 203517-69-5 CAPLUS
CN Benzenesulfonamide, 4-[5-(4-fluoro-3-methylphenyl)-2-(phenylmethyl)-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 203517-70-8 CAPLUS
CN Benzenesulfonamide, 4-[5-(3-fluoro-4-methoxyphenyl)-2-(phenylmethyl)-4-oxazolyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:53966 CAPLUS
DOCUMENT NUMBER: 126:74828
TITLE: Preparation of substituted oxazoles as antiinflammatories.
INVENTOR(S): Talley, John J.; Bertenshaw, Stephen; Rogier, Donald J., Jr.; Graneto, Matthew; Brown, David L.; Devadas, Balekudru; Lu, Hwang-Fun; Sikorski, James A.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: PCT Int. Appl., 243 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9636617	A1	19961121	WO 1996-US6992	19960516
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
CA 2221692	AA	19961121	CA 1996-2221692	19960516
AU 9658603	A1	19961129	AU 1996-58603	19960516
EP 825989	A1	19980304	EP 1996-920231	19960516
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 11509835	T2	19990831	JP 1996-535029	19960516
PRIORITY APPLN. INFO.:			US 1995-445312 A	19950519
			WO 1996-US6992 W	19960516

OTHER SOURCE(S): MARPAT 126:74828
GI



I

AB Title compds. (I; R2 = alkyl, amino; R4 = H, alkyl, alkylamino, alkoxy, halo; R5 = halo, SH, carboxyalkylthio, aminocarbonyl, amino acid residue, haloalkoxy, aryloxy, phosphonylalkyl, cyanoalkyl, heterocyclylalkyl, etc.), were prepared Thus, 4-(4-fluorophenyl)-2-(2-phenylethyl)-5-(4-

methylsulfonyphenyl)oxazole, prepared from 1-(4-fluorophenyl)-2-(4-methylthiophenyl)ethanone, at 10 mg/kg gave 41% inhibition of edema in the carrageenan foot pad edema test.

IT **185343-45-7P 185343-46-8P 185343-47-9P**
185343-48-0P 185343-49-1P 185343-50-4P
185344-55-2P 185344-58-5P 185344-59-6P
185344-60-9P 185344-61-0P 185344-62-1P
185344-64-3P 185344-66-5P 185344-68-7P
185344-69-8P 185345-96-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted oxazoles as antiinflammatories)

RN 185343-45-7 CAPLUS
CN Benzenesulfonamide, 4-methyl-3-[5-phenyl-2-(trifluoromethyl)-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 185343-46-8 CAPLUS
CN Benzenesulfonamide, 5-[5-[4-(aminosulfonyl)phenyl]-2-(trifluoromethyl)-4-oxazolyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 185343-47-9 CAPLUS
CN Benzenesulfonamide, 4-methyl-3-[4-phenyl-2-(trifluoromethyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 185343-48-0 CAPLUS
CN 2-Oxazoleacetic acid, 4-[4-(aminosulfonyl)phenyl]-α-bromo-5-(3-fluoro-4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 185343-49-1 CAPLUS
CN Benzenesulfonamide, 5-[5-[4-(aminosulfonyl)phenyl]-2-(trifluoromethyl)-4-oxazolyl]-3-fluoro-2-methoxy- (9CI) (CA INDEX NAME)



RN 185343-50-4 CAPLUS
CN Benzenesulfonamide, 3-fluoro-4-methoxy-5-[5-phenyl-2-(trifluoromethyl)-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 185344-55-2 CAPLUS
CN Benzenesulfonamide, 4-[5-(3-fluoro-4-methoxyphenyl)-2-(trifluoromethyl)-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 185344-58-5 CAPLUS
CN 2-Oxazoleacetic acid, 4-[4-(aminosulfonyl)phenyl]-5-(3-fluoro-4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 185344-59-6 CAPLUS
CN Oxazole, 4-(4-methylphenyl)-5-[4-(methylsulfonyl)phenyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 185344-60-9 CAPLUS
CN Benzenesulfonamide, 4-[5-(3-fluoro-4-methoxyphenyl)-2-methyl-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 185344-61-0 CAPLUS
CN Oxazole, 5-(3-fluoro-4-methoxyphenyl)-4-[4-(methylsulfonyl)phenyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 185344-62-1 CAPLUS
CN Benzenesulfonamide, 4-[5-(3-bromo-5-fluoro-4-methoxyphenyl)-2-(trifluoromethyl)-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 185344-64-3 CAPLUS
CN Oxazole, 4-(3-fluoro-4-methoxyphenyl)-5-[4-(methylsulfonyl)phenyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 185344-66-5 CAPLUS
CN Benzenesulfonamide, 4-[4-(3-fluoro-4-methoxyphenyl)-2-(trifluoromethyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 185344-68-7 CAPLUS
CN Benzenesulfonamide, 4-[5-(3-chloro-4-methoxyphenyl)-2-(trifluoromethyl)-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 185344-69-8 CAPLUS
CN Benzenesulfonamide, 4-[4-(3-fluoro-4-methoxyphenyl)-2-(hydroxymethyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 185345-96-4 CAPLUS
CN 2-Oxazoleacetic acid, 4-[4-(aminosulfonyl)phenyl]-5-(3-fluoro-4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



IT **185345-02-2P 185345-32-8P 185345-34-0P**
185345-37-3P 185345-41-9P 185345-42-0P
185345-45-3P 185345-51-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted oxazoles as antiinflammatories)
RN 185345-02-2 CAPLUS
CN 2-Oxazoleacetic acid, 5-(3-fluoro-4-methoxyphenyl)-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 185345-32-8 CAPLUS
CN Oxazole, 5-(3-fluoro-4-methoxyphenyl)-4-phenyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 185345-34-0 CAPLUS
CN Oxazole, 4-(4-methylphenyl)-5-phenyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 185345-37-3 CAPLUS
CN Oxazole, 5-(4-methylphenyl)-4-phenyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 185345-41-9 CAPLUS
CN Oxazole, 4-(4-methylphenyl)-5-[4-(methylthio)phenyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 185345-42-0 CAPLUS
CN Oxazole, 5-(3-fluoro-4-methoxyphenyl)-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 185345-45-3 CAPLUS
CN Oxazole, 5-(3-fluoro-4-methoxyphenyl)-4-[4-(methylthio)phenyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 185345-51-1 CAPLUS
CN Oxazole, 5-(3-bromo-5-fluoro-4-methoxyphenyl)-4-phenyl-2-(trifluoromethyl)-
(9CI) (CA INDEX NAME)



L10 ANSWER 7 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1993:213054 CAPLUS
DOCUMENT NUMBER: 118:213054
TITLE: Preparation of [(hydroxyamino)alkyl]diphenyloxazoles and their reaction products as antiinflammatory compounds
INVENTOR(S): Barreau, Michel; Kryvenko, Michel; Lavergne, Marc Pierre; Techer, Auguste
PATENT ASSIGNEE(S): Laboratoire Roger Bellon, Fr.
SOURCE: Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 517591	A1	19921209	EP 1992-401527	19920604
R: PT				
FR 2677477	A1	19921211	FR 1991-6847	19910606
FR 2677477	B1	19930820		
ZA 9204038	A	19931203	ZA 1992-4038	19920603
WO 9221665	A1	19921210	WO 1992-FR493	19920604
W: AU, CA, CS, FI, HU, JP, KR, NO, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
AU 9218955	A1	19930108	AU 1992-18955	19920604
PRIORITY APPLN. INFO.:			FR 1991-6847 A	19910606
			WO 1992-FR493 A	19920604

OTHER SOURCE(S): MARPAT 118:213054
GI



I



II

AB Isoxazoles I (R = H, C1-2 alkyl; R1, R2 = H, halo, C1-4 linear or branched alkoxy; n = 3-6), their salts, isomers, and isomeric mixts., were prepared as antiinflammatories. Title compound II was prepared and formulated. I inhibited 5-lipoxygenase in rat basophil leukemia prepns. with IC50 = 300-600 nM.

IT **146678-24-2P 146678-28-6P 146678-40-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and conversion of, to acetohydroxamic acid)

RN 146678-24-2 CAPLUS
CN Acetamide, N-(acetyloxy)-N-[6-[4,5-bis(4-methoxyphenyl)-2-oxazolyl]hexyl]- (9CI) (CA INDEX NAME)



RN 146678-28-6 CAPLUS
CN Acetamide, N-(acetyloxy)-N-[6-[4,5-bis(4-methoxyphenyl)-2-oxazolyl]-1-methylhexyl]- (9CI) (CA INDEX NAME)



RN 146678-40-2 CAPLUS
CN Acetamide, N-(acetyloxy)-N-[6-[4-(4-chlorophenyl)-5-(4-methoxyphenyl)-2-oxazolyl]hexyl]- (9CI) (CA INDEX NAME)



IT **146678-12-8P 146678-15-1P 146678-30-0P 146678-34-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and conversion of, to hydroxylamine, in preparation of antiinflammatory)

RN 146678-12-8 CAPLUS
CN 4-Isoxazolecarboxylic acid, 2-[6-[4,5-bis(4-methoxyphenyl)-2-oxazolyl]hexyl]-2,5-dihydro-3-methyl-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 146678-15-1 CAPLUS
CN 4-Isoxazolecarboxylic acid, 2-[5-[4,5-bis(4-methoxyphenyl)-2-oxazolyl]pentyl]-2,5-dihydro-3-methyl-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 146678-30-0 CAPLUS
CN 2-Heptanone, 7-[4,5-bis(4-methoxyphenyl)-2-oxazolyl]-, oxime, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 146678-34-4 CAPLUS
CN 2-Heptanone, 7-[4,5-bis(4-methoxyphenyl)-2-oxazolyl]-, oxime, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **146678-43-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidation of, to aldehyde, in preparation of antiinflammatory)
RN 146678-43-5 CAPLUS
CN 2-Oxazolehexanol, 4-(4-chlorophenyl)-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



IT **146678-33-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oximation of, in preparation of antiinflammatory)
RN 146678-33-3 CAPLUS
CN 2-Heptanone, 7-[4,5-bis(4-methoxyphenyl)-2-oxazolyl]- (9CI) (CA INDEX NAME)



IT **146678-42-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and oximation-cyanoborohydride reduction of, in preparation of antiinflammatory)
RN 146678-42-4 CAPLUS
CN 2-Oxazolehexanal, 4-(4-chlorophenyl)-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



IT **146678-31-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with deprotonated acetyl acetate, in preparation of
antiinflammatory)
RN 146678-31-1 CAPLUS
CN Oxazole, 2-(4-bromobutyl)-4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



IT **139503-48-3P 146678-13-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with methylhydroxyisoxazolecarboxylate, in preparation of antiinflammatory)
RN 139503-48-3 CAPLUS
CN Oxazole, 2-(5-bromopentyl)-4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 146678-13-9 CAPLUS
CN Oxazole, 2-(6-bromohexyl)-4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



IT **146678-11-7P 146678-25-3P 146678-26-4P**
146678-27-5P 146678-29-7P 146678-41-3P
146773-49-1P 146773-58-2P 146962-63-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antiinflammatory)
RN 146678-11-7 CAPLUS
CN Urea, N-[6-[4,5-bis(4-methoxyphenyl)-2-oxazolyl]hexyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 146678-25-3 CAPLUS
CN Acetamide, N-[6-[4,5-bis(4-methoxyphenyl)-2-oxazolyl]hexyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 146678-26-4 CAPLUS
CN Propanamide, N-[6-[4,5-bis(4-methoxyphenyl)-2-oxazolyl]hexyl]-N-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



RN 146678-27-5 CAPLUS
CN 2-Oxazolehexanamine, N-hydroxy-4,5-bis(4-methoxyphenyl)-α-methyl- (9CI) (CA INDEX NAME)



RN 146678-29-7 CAPLUS
CN Acetamide, N-[6-[4,5-bis(4-methoxyphenyl)-2-oxazolyl]-1-methylhexyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 146678-41-3 CAPLUS
CN Acetamide, N-[6-[4-(4-chlorophenyl)-5-(4-methoxyphenyl)-2-oxazolyl]hexyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 146773-49-1 CAPLUS
CN 2-Oxazolepentanamine, N-hydroxy-4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 146773-58-2 CAPLUS
CN Urea, N-[5-[4,5-bis(4-methoxyphenyl)-2-oxazolyl]pentyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 146962-63-2 CAPLUS
CN 2-Oxazolehexanamine, N-hydroxy-4,5-bis(4-methoxyphenyl)-α-methyl-,

ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 146678-27-5
CMF C24 H30 N2 O4



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT **146962-62-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiinflammatory)
RN 146962-62-1 CAPLUS
CN 2-Oxazolehexanamine, N-hydroxy-4,5-bis(4-methoxyphenyl)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 146962-61-0
CMF C23 H28 N2 O4



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT **146678-32-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for antiinflammatory)
RN 146678-32-2 CAPLUS
CN 2-Oxazolehexanoic acid, α-acetyl-4,5-bis(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 9 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1992:151775 CAPLUS
DOCUMENT NUMBER: 116:151775
TITLE: Novel tetrazole-containing oxazole derivatives, their preparation as antiinflammatories, and pharmaceutical compositions containing them
INVENTOR(S): Barreau, Michel; Kryvenko, Michel; Lavergne, Marc Pierre; Techer, Auguste
PATENT ASSIGNEE(S): Laboratoire Roger Bellon S. A., Fr.
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9119714	A1	19911226	WO 1991-FR473	19910613
W: AU, CA, FI, HU, JP, KR, NO, SU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
FR 2663331	A1	19911220	FR 1990-7388	19900614
CA 2080340	AA	19911215	CA 1991-2080340	19910613
AU 9180583	A1	19920107	AU 1991-80583	19910613
AU 644454	B2	19931209		
ZA 9104516	A	19920325	ZA 1991-4516	19910613
EP 533827	A1	19930331	EP 1991-912243	19910613
EP 533827	B1	19940824		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
HU 62888	A2	19930628	HU 1992-3942	19910613
JP 05507710	T2	19931104	JP 1991-511371	19910613
ES 2063513	T3	19950101	ES 1991-912243	19910613
NO 9204634	A	19921201	NO 1992-4634	19921201
US 5403852	A	19950404	US 1992-960428	19921211

PRIORITY APPLN. INFO.: FR 1990-7388 A 19900614
WO 1991-FR473 A 19910613
OTHER SOURCE(S): MARPAT 116:151775
GI



I

AB Title compds. I (R, R' = H, alkyl; R1, R2 = H, halo, alkoxy; n = 3-6) were

prepared as antiinflammatories. For example, 2-amino-1,2-bis-(4-methoxyphenyl)ethanone HCl salt underwent a sequence of amidation with Br(CH2)5COCl, cyclization to an isoxazole by POCl3, alkylative coupling of the bromide with Et cyanoacetate, alkaline saponification, and decarboxylation to give
7-[4,5-bis-(4-methoxyphenyl)-2-oxazolyl]heptanenitrile. Treatment of this nitrile with NaN3 and NH4Cl in DMF at 105° gave 43.7% I (R1 = R2 = MeO, R = R' = H, n = 5). I inhibited binding of [3H]-LTB4 to LTB4 receptors of guinea pig spleen membrane with IC50 = 5-500 nM. I were orally active and showed low toxicity in mice. I are also useful as antipyretics and analgesics (no data). Eleven addnl., similar syntheses and a standard tablet formulation are described.

IT **139503-34-7P 139503-35-8P 139503-39-2P**
139503-40-5P 139503-41-6P 139503-42-7P
139503-45-0P 139503-46-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antiinflammatory)

RN 139503-34-7 CAPLUS
CN 1H-Tetrazole, 5-[6-[4,5-bis(4-methoxyphenyl)-2-oxazolyl]hexyl]- (9CI) (CA INDEX NAME)



RN 139503-35-8 CAPLUS
CN 1H-Tetrazole, 5-[5-[4,5-bis(4-methoxyphenyl)-2-oxazolyl]pentyl]- (9CI) (CA INDEX NAME)



RN 139503-39-2 CAPLUS
CN 1H-Tetrazole, 5-[6-[4-(4-chlorophenyl)-5-(4-methoxyphenyl)-2-oxazolyl]hexyl]- (9CI) (CA INDEX NAME)



RN 139503-40-5 CAPLUS
CN 1H-Tetrazole, 5-[5-[4-(4-chlorophenyl)-5-(4-methoxyphenyl)-2-oxazolyl]pentyl]- (9CI) (CA INDEX NAME)



RN 139503-41-6 CAPLUS
CN 1H-Tetrazole, 5-[6-[5-(4-chlorophenyl)-4-(4-methoxyphenyl)-2-oxazolyl]hexyl]- (9CI) (CA INDEX NAME)



RN 139503-42-7 CAPLUS
CN 1H-Tetrazole, 5-[6-[4,5-bis(4-methoxyphenyl)-2-oxazolyl]-1-methylhexyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 139503-45-0 CAPLUS
CN 1H-Tetrazole, 5-[6-[4,5-bis(4-methoxyphenyl)-2-oxazolyl]-1,1-dimethylhexyl]- (9CI) (CA INDEX NAME)



RN 139503-46-1 CAPLUS
CN 1H-Tetrazole, 5-[6-[4,5-bis(4-methoxyphenyl)-2-oxazolyl]-1-methylhexyl]- (9CI) (CA INDEX NAME)



IT **139503-47-2P 139503-48-3P 139503-49-4P**
139503-50-7P 139503-52-9P 139503-62-1P
139503-63-2P 139503-64-3P 139503-66-5P

139503-67-6P 139503-70-1P 139503-80-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for antiinflammatory)
RN 139503-47-2 CAPLUS
CN 2-Oxazoleheptanenitrile, 4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 139503-48-3 CAPLUS
CN Oxazole, 2-(5-bromopentyl)-4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 139503-49-4 CAPLUS
CN 2-Oxazoleheptanoic acid, α-cyano-4,5-bis(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 139503-50-7 CAPLUS
CN 2-Oxazoleheptanoic acid, α-cyano-4,5-bis(4-methoxyphenyl)- (9CI)

(CA INDEX NAME)



RN 139503-52-9 CAPLUS
CN 2-Oxazolehexanenitrile, 4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 139503-62-1 CAPLUS
CN Oxazole, 2-(6-bromohexyl)-4-(4-chlorophenyl)-5-(4-methoxyphenyl)- (9CI)
(CA INDEX NAME)



RN 139503-63-2 CAPLUS
CN 2-Oxazoleheptanenitrile, 4-(4-chlorophenyl)-5-(4-methoxyphenyl)- (9CI)
(CA INDEX NAME)



RN 139503-64-3 CAPLUS
CN 2-Oxazolehexanenitrile, 4-(4-chlorophenyl)-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 139503-66-5 CAPLUS
CN Oxazole, 2-(5-bromopentyl)-4-(4-chlorophenyl)-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 139503-67-6 CAPLUS
CN 2-Oxazoleheptanenitrile, 5-(4-chlorophenyl)-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 139503-70-1 CAPLUS
CN 2-Oxazoleheptanenitrile, 4,5-bis(4-methoxyphenyl)-α-methyl- (9CI) (CA INDEX NAME)



RN 139503-80-3 CAPLUS
CN 2-Oxazoleheptanenitrile, 4,5-bis(4-methoxyphenyl)-α,α-dimethyl- (9CI) (CA INDEX NAME)



L10 ANSWER 11 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1963:59724 CAPLUS
DOCUMENT NUMBER: 58:59724
ORIGINAL REFERENCE NO.: 58:10186a-c
TITLE: Substitution of 4,5-diphenyloxazoles and -imidazoles, and some related compounds
AUTHOR(S): van Es, T.; Backeberg, O. G.
CORPORATE SOURCE: Univ. Witwatersrand, Johannesburg, S. Afr.
SOURCE: Journal of the Chemical Society, Abstracts (1963) 1363-70
CODEN: JCSAAZ; ISSN: 0590-9791
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
GI For diagram(s), see printed CA Issue.
AB cf. following abstract Substitution of the phenyl groups in 2-methyl-4,5-diphenyloxazole (I), as well as in some other similar oxazoles and imidazoles, is described; nitration, sulfonation, and chlorosulfonation of most of these compds. occur in the para positions, in one or in both of the phenyl groups. The nitro derivs. have been reduced to the amines which were diazotized and subjected to the usual replacement reactions.
IT **58764-21-9**, Benzoic acid, 4,4'-(2-methyl-4,5-oxazolediyl)di-, dimethyl ester **92856-11-6**, Phenol, 4,4'-(2-methyl-4,5-oxazolediyl)di- **92866-12-1**, Phenol, 2,6-dibromo-4-[2-methyl-4-(p-nitrophenyl)-5-oxazolyl]- **92868-72-9**, Phenol, p-[2-methyl-4-(p-nitrophenyl)-5-oxazolyl]- **93013-86-6**, Phenol, p-[4-(p-aminophenyl)-2-methyl-5-oxazolyl]- **93324-41-5**, Benzoic acid, p-[2-methyl-4-(p-sulfamoylphenyl)-5-oxazolyl]- **93325-29-2**, Benzoic acid, p-(2-methyl-4-phenyl-5-oxazolyl)- **93326-18-2**, Benzenesulfonamide, p-[5-(p-cyanophenyl)-2-methyl-4-oxazolyl]- **93326-51-3**, Benzonitrile, p-(2-methyl-4-phenyl-5-oxazolyl)- **93327-05-0**, Benzoic acid, p-[2-methyl-4-(p-nitrophenyl)-5-oxazolyl]- **93329-16-9**, Benzonitrile, p-[2-methyl-4-(p-nitrophenyl)-5-oxazolyl]- **93729-18-1**, Benzoic acid, p-(2-methyl-4-phenyl-5-oxazolyl)-, methyl ester **93819-35-3**, Benzonitrile, 4,4'-(2-methyl-4,5-oxazolediyl)di- **94210-02-3**, Benzoic acid, p-[2-methyl-4-(p-sulfamoylphenyl)-5-oxazolyl]-, methyl ester **94298-59-6**, Phenol, p-(2-methyl-4-phenyl-5-oxazolyl)- **94538-68-8**, Benzenesulfonamide, p-[5-(p-hydroxyphenyl)-2-methyl-4-oxazolyl]- **94960-14-2**, Benzamide, 4,4'-(2-methyl-4,5-oxazolediyl)bis- **95813-55-1**, Benzoic acid, p-[2-methyl-4-(p-nitrophenyl)-5-oxazolyl]-, methyl ester
(preparation of)
RN 58764-21-9 CAPLUS
CN Benzoic acid, 4,4'-(2-methyl-4,5-oxazolediyl)bis-, dimethyl ester (9CI) (CA INDEX NAME)



RN 92856-11-6 CAPLUS
CN Phenol, 4,4'-(2-methyl-4,5-oxazolediyl)bis- (9CI) (CA INDEX NAME)



RN 92866-12-1 CAPLUS
CN Phenol, 2,6-dibromo-4-[2-methyl-4-(p-nitrophenyl)-5-oxazolyl]- (7CI) (CA INDEX NAME)



RN 92868-72-9 CAPLUS
CN Phenol, p-[2-methyl-4-(p-nitrophenyl)-5-oxazolyl]- (7CI) (CA INDEX NAME)



RN 93013-86-6 CAPLUS
CN Phenol, p-[4-(p-aminophenyl)-2-methyl-5-oxazolyl]- (7CI) (CA INDEX NAME)



RN 93324-41-5 CAPLUS
CN Benzoic acid, p-[2-methyl-4-(p-sulfamoylphenyl)-5-oxazolyl]- (7CI) (CA INDEX NAME)



RN 93325-29-2 CAPLUS
CN Benzoic acid, p-(2-methyl-4-phenyl-5-oxazolyl)- (7CI) (CA INDEX NAME)



RN 93326-18-2 CAPLUS
CN Benzenesulfonamide, p-[5-(p-cyanophenyl)-2-methyl-4-oxazolyl]- (7CI) (CA INDEX NAME)



RN 93326-51-3 CAPLUS
CN Benzonitrile, p-(2-methyl-4-phenyl-5-oxazolyl)- (7CI) (CA INDEX NAME)



RN 93327-05-0 CAPLUS
CN Benzoic acid, p-[2-methyl-4-(p-nitrophenyl)-5-oxazolyl]- (7CI) (CA INDEX NAME)



RN 93329-16-9 CAPLUS
CN Benzonitrile, p-[2-methyl-4-(p-nitrophenyl)-5-oxazolyl]- (7CI) (CA INDEX NAME)



RN 93729-18-1 CAPLUS
CN Benzoic acid, p-(2-methyl-4-phenyl-5-oxazolyl)-, methyl ester (7CI) (CA INDEX NAME)



RN 93819-35-3 CAPLUS
CN Benzonitrile, 4,4'-(2-methyl-4,5-oxazolediyl)di- (7CI) (CA INDEX NAME)



RN 94210-02-3 CAPLUS
CN Benzoic acid, p-[2-methyl-4-(p-sulfamoylphenyl)-5-oxazolyl]-, methyl ester (7CI) (CA INDEX NAME)



RN 94298-59-6 CAPLUS
CN Phenol, p-(2-methyl-4-phenyl-5-oxazolyl)- (7CI) (CA INDEX NAME)



RN 94538-68-8 CAPLUS
CN Benzenesulfonamide, p-[5-(p-hydroxyphenyl)-2-methyl-4-oxazolyl]- (7CI) (CA INDEX NAME)



RN 94960-14-2 CAPLUS
CN Benzamide, 4,4'-(2-methyl-4,5-oxazolediyl)bis- (7CI) (CA INDEX NAME)



RN 95813-55-1 CAPLUS
CN Benzoic acid, p-[2-methyl-4-(p-nitrophenyl)-5-oxazolyl]-, methyl ester (7CI) (CA INDEX NAME)



L10 ANSWER 12 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:84397 CAPLUS
DOCUMENT NUMBER: 78:84397
TITLE: Pyrrole derivatives
INVENTOR(S): Dahm, Johann; Borck, Joachim; Wild, Albrecht; Hovy, Jan Willem
PATENT ASSIGNEE(S): Merck Patent G.m.b.H.
SOURCE: Ger. Offen., 116 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2129012	A1	19730104	DE 1971-2129012	19710611
ZA 7203502	A	19730328	ZA 1972-3502	19720522
GB 1331408	A	19730926	GB 1972-24195	19720523
RO 60483	P	19760815	RO 1972-71023	19720525
CS 167984	P	19760528	CS 1972-3691	19720529
CS 167985	P	19760528	CS 1972-4413	19720529
CS 167986	P	19760528	CS 1972-4414	19720529
CS 167987	P	19760528	CS 1972-4415	19720529
CS 167988	P	19760528	CS 1972-4416	19720529
CS 167989	P	19760528	CS 1972-4417	19720529
CH 584210	A	19770131	CH 1976-289	19720531
CH 584700	A	19770215	CH 1972-8062	19720531
CH 584701	A	19770215	CH 1976-287	19720531
CH 584702	A	19770215	CH 1976-288	19720531
CH 585213	A	19770228	CH 1976-285	19720531
CH 590856	A	19770831	CH 1976-286	19720531
SE 381467	B	19751208	SE 1972-7357	19720605
US 3933840	A	19760120	US 1972-260307	19720606
AT 7401365	A	19750515	AT 1972-136574	19720607
AT 7401366	A	19750515	AT 1972-136674	19720607
AT 7401367	A	19750515	AT 1972-136774	19720607
AT 7401368	A	19750515	AT 1972-136874	19720607
AT 7204895	A	19750615	AT 1972-4895	19720607
AT 328440	B	19760325		
AT 323158	B	19750625	AT 1972-323158	19720607
AT 327889	B	19760225	AT 1972-327889	19720607
AT 327890	B	19760225	AT 1972-327890	19720607
AT 327891	B	19760225	AT 1972-327891	19720607
AT 327892	B	19760225	AT 1972-327892	19720607
NL 7207784	A	19721213	NL 1972-7784	19720608
BE 784682	A1	19721211	BE 1972-118528	19720609
FR 2140632	A1	19730119	FR 1972-20858	19720609
DD 97206	C	19730423	DD 1972-163592	19720609
HU 166271	P	19750228	HU 1972-ME1505	19720609
PL 79513	P	19750630	PL 1972-155917	19720609
CA 1008863	A1	19770419	CA 1972-144331	19720609
ES 403741	A1	19760401	ES 1972-403741	19720610
JP 57028705	B4	19820618	JP 1972-57757	19720612
ES 439448	A1	19770301	ES 1975-439448	19750715
US 4051250	A	19770927	US 1975-624447	19751021

PRIORITY APPLN. INFO.:
DE 1971-2129012 A 19710611
US 1972-260307 A3 19720606

GI For diagram(s), see printed CA Issue.

AB The oxazolylmercaptoalkanoates I (X = O; R and R1 = Ph, p-MeC6H4, p-ClC6H4, p-MeOC6H4, 3,4-(MeO)2C6H3, methylenedioxyphenyl, p-FC6H4, o-ClC6H4, p-Me2NC6H4; R2 = Et; Q = CH2, CMe2, CH2CH2, CHEt) were prepared by treating the 2-mercaptooxazole with BrQCO2Et. I (R2 = Et) were hydrolyzed to the acids I (R2 = H). Analogous I (X = S) were prepared from the 2-mercaptothiazoles.

IT **40198-31-0P 40198-35-4P 40198-36-5P**
40198-48-9P 40198-49-0P 40198-56-9P
40198-57-0P 40198-58-1P 40198-59-2P
40198-60-5P 40198-86-5P 40198-87-6P
40198-89-8P 40198-91-2P 40198-92-3P
40331-11-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 40198-31-0 CAPLUS

CN Acetic acid, [[4,5-bis(4-methylphenyl)-2-oxazolyl]thio]-, ethyl ester (9CI) (CA INDEX NAME)



RN 40198-35-4 CAPLUS

CN Acetic acid, [[4,5-bis(4-methoxyphenyl)-2-oxazolyl]thio]-, ethyl ester (9CI) (CA INDEX NAME)



RN 40198-36-5 CAPLUS

CN Acetic acid, [[4,5-bis(3,4-dimethoxyphenyl)-2-oxazolyl]thio]-, ethyl ester (9CI) (CA INDEX NAME)



RN 40198-48-9 CAPLUS
CN Acetic acid, [[4,5-bis(4-methylphenyl)-2-oxazolyl]thio]- (9CI) (CA INDEX NAME)



RN 40198-49-0 CAPLUS
CN Acetic acid, [[4,5-bis[4-(1-methylethyl)phenyl]-2-oxazolyl]thio]- (9CI) (CA INDEX NAME)



RN 40198-56-9 CAPLUS
CN Acetic acid, [[4-(4-methoxyphenyl)-5-phenyl-2-oxazolyl]thio]- (9CI) (CA INDEX NAME)



RN 40198-57-0 CAPLUS
CN Acetic acid, [[4,5-bis(2-methoxyphenyl)-2-oxazolyl]thio]- (9CI) (CA INDEX NAME)



RN 40198-58-1 CAPLUS
CN Acetic acid, [[4,5-bis(4-methoxyphenyl)-2-oxazolyl]thio]- (9CI) (CA INDEX NAME)



RN 40198-59-2 CAPLUS
CN Acetic acid, [[5-(2-chlorophenyl)-4-(4-methoxyphenyl)-2-oxazolyl]thio]- (9CI) (CA INDEX NAME)



RN 40198-60-5 CAPLUS
CN Acetic acid, [[4,5-bis(3,4-dimethoxyphenyl)-2-oxazolyl]thio]- (9CI) (CA INDEX NAME)



RN 40198-86-5 CAPLUS
CN Propanoic acid, 2-[[4,5-bis(4-methylphenyl)-2-oxazolyl]thio]- (9CI) (CA INDEX NAME)



RN 40198-87-6 CAPLUS
CN Propanoic acid, 2-[[4,5-bis[4-(1-methylethyl)phenyl]-2-oxazolyl]thio]- (9CI) (CA INDEX NAME)



RN 40198-89-8 CAPLUS
CN Propanoic acid, 2-[[4,5-bis(4-methoxyphenyl)-2-oxazolyl]thio]- (9CI) (CA INDEX NAME)



RN 40198-91-2 CAPLUS
CN Butanoic acid, 2-[[4,5-bis(4-methylphenyl)-2-oxazolyl]thio]- (9CI) (CA INDEX NAME)



RN 40198-92-3 CAPLUS
CN Butanoic acid, 2-[[4,5-bis[4-(1-methylethyl)phenyl]-2-oxazolyl]thio]- (9CI) (CA INDEX NAME)



RN 40331-11-1 CAPLUS
CN Acetic acid, [[4,5-bis(3-methoxyphenyl)-2-oxazolyl]thio]- (9CI) (CA INDEX NAME)


HO2C— CH2— S
N
O
OMe
MeO

L10 ANSWER 18 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1975:606272 CAPLUS
DOCUMENT NUMBER: 83:206272
TITLE: 2-Alkyl- and 2-cycloalkyl-4,5-bisphenylimidazoles
INVENTOR(S): Fitzi, Konrad; Pfister, Rudolf
PATENT ASSIGNEE(S): Ciba-Geigy Corp., Switz.
SOURCE: U.S., 12 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3901908	A	19750826	US 1973-376760	19730705
US 3784691	A	19740108	US 1972-283135	19720823
PRIORITY APPLN. INFO.:			US 1970-102131 A2	19701228

GI For diagram(s), see printed CA Issue.
AB The imidazoles I (R = Et, Me2CH, Bu, cyclopropyl, etc.; R1, R2 = H, p-MeO, p-Me, etc.) were prepared by cyclization of R1C6H4COCOC6H4R2 with RCHO and NH3, cyclization of R1C6H4COCH(C6H4R2)NHCOR with NH3, cyclization of R1C6H4CH(OH)COC6H4R2 with NH3 and RCHO, II with NH3, and cyclization of amidines with acetophenones. Thus, p-MeOC6H4COCOC6H4OMe-p was treated with Me2CHCHO followed by NH3 to give 55% I (R = Me2CH, R1 = R2 = p-MeO). At 1-200 mg/kg I were antipyretic. I were also antiinflammatory.
IT **33420-71-2P 33420-72-3P 33420-73-4P**
33420-74-5P 33425-71-7P 54551-64-3P
54551-65-4P 57297-21-9P 57297-22-0P
57297-23-1P 57297-24-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with ammonia)
RN 33420-71-2 CAPLUS
CN Oxazole, 4,5-bis(4-methoxyphenyl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 33420-72-3 CAPLUS
CN Oxazole, 2-cyclopropyl-4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 33420-73-4 CAPLUS
CN Oxazole, 4-(4-methoxyphenyl)-2-(1-methylethyl)-5-phenyl- (9CI) (CA INDEX NAME)



RN 33420-74-5 CAPLUS
CN Oxazole, 2-(1,1-dimethylethyl)-4,5-bis(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 33425-71-7 CAPLUS
CN Oxazole, 2-(1,1-dimethylethyl)-4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 54551-64-3 CAPLUS
CN Phenol, 4-[2-(1,1-dimethylethyl)-5-phenyl-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 54551-65-4 CAPLUS
CN Oxazole, 5-(4-chlorophenyl)-2-(1,1-dimethylethyl)-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 57297-21-9 CAPLUS
CN Oxazole, 4,5-bis(4-methoxyphenyl)-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 57297-22-0 CAPLUS
CN Oxazole, 2-hexyl-4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 57297-23-1 CAPLUS
CN Oxazole, 2-(1,1-dimethylethyl)-4-(4-methoxyphenyl)-5-phenyl- (9CI) (CA INDEX NAME)



RN 57297-24-2 CAPLUS
CN Oxazole, 2-cyclopropyl-4-(4-methoxyphenyl)-5-phenyl- (9CI) (CA INDEX NAME)



L10 ANSWER 19 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1984:22620 CAPLUS
DOCUMENT NUMBER: 100:22620
TITLE: Nonsteroidal antiinflammatory agents. XVII. 4,5-Bis(4-methoxyphenyl)-2-(arylthio)azoles with antiinflammatory activity
AUTHOR(S): Klose, Walter; Niedballa, Ulrich; Schwarz, Katica; Boettcher, Irmgard
CORPORATE SOURCE: Forschungslab., Schering A.-G., Berlin, D-1000/65, Fed. Rep. Ger.
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1983), 316(11), 941-51
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: German
GI



I

AB The title azoles I (X = NH, S, O, R = Ph, n = 0-2; X = NH, R = 4-FC6H4, n = 0, 1, R = 2-thienyl, n = 0, 2; X = S, R = 4-FC6H4, 2-thienyl, n = 0; X = O, R = 4-FC6H4, n = 0-2; R = 2-thienyl, n = 0, 2) were prepared from p,p'-anisoin or p,p'-deoxyanisoin via cyclization with thiocyanates or H2NCS2NH4 and their antiinflammatory activities compared. Oxazole derivs. show no antiinflammatory activity, thiazoles have an intermediate activity, and imidazoles the greatest activity. In an acute test, imidazoles were not ulcerogenic.

IT **84589-36-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and arylation of)
RN 84589-36-6 CAPLUS
CN 2(3H)-Oxazolethione, 4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



IT **14003-68-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with di-Ph disulfide)
RN 14003-68-0 CAPLUS
CN Oxazole, 4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



IT **88264-20-4P 88264-21-5P 88264-23-7P**
88264-24-8P 88264-25-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, and antiinflammatory activity of)
RN 88264-20-4 CAPLUS
CN Oxazole, 4,5-bis(4-methoxyphenyl)-2-(phenylsulfinyl)- (9CI) (CA INDEX NAME)



RN 88264-21-5 CAPLUS
CN Oxazole, 2-[(4-fluorophenyl)sulfinyl]-4,5-bis(4-methoxyphenyl)- (9CI) (CA

INDEX NAME)



RN 88264-23-7 CAPLUS
CN Oxazole, 4,5-bis(4-methoxyphenyl)-2-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 88264-24-8 CAPLUS
CN Oxazole, 2-[(4-fluorophenyl)sulfonyl]-4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 88264-25-9 CAPLUS
CN Oxazole, 4,5-bis(4-methoxyphenyl)-2-(2-thienylsulfonyl)- (9CI) (CA INDEX NAME)



IT **88264-16-8P 88264-17-9P 88264-18-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, oxidation, and antiinflammatory activity of)
RN 88264-16-8 CAPLUS
CN Oxazole, 4,5-bis(4-methoxyphenyl)-2-(phenylthio)- (9CI) (CA INDEX NAME)



RN 88264-17-9 CAPLUS
CN Oxazole, 2-[(4-fluorophenyl)thio]-4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 88264-18-0 CAPLUS
CN Oxazole, 4,5-bis(4-methoxyphenyl)-2-(2-thienylthio)- (9CI) (CA INDEX NAME)


S
S
N
O
OMe
OMe

L10 ANSWER 25 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1975:43425 CAPLUS
DOCUMENT NUMBER: 82:43425
TITLE: Imidazole derivatives
INVENTOR(S): Fitzi, Konrad; Pfister, Rudolf
PATENT ASSIGNEE(S): Ciba-Geigy A.-G.
SOURCE: Patentschrift (Switz.), 3 pp. Addn. to Swiss 524,614.
CODEN: SWXXAS
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CH 554872	A	19741015	CH 1973-15160	19701204
PRIORITY APPLN. INFO.:			CH 1973-15160 A	19701204

GI For diagram(s), see printed CA Issue.
AB Eleven diphenylimidazoles I (R = CHMe2, CMe3; R1 = MeSO2, OH, OMe; R2 = H, o-, m-, p-Cl, m-Me, OMe) were prepared by reaction of the oxazoles II with NH3 and(or) HCONH2.
IT **54551-64-3 54551-65-4 54551-66-5**
54551-67-6 54551-68-7 54551-69-8
54551-70-1 54551-81-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with ammonia and (or) formamide)
RN 54551-64-3 CAPLUS
CN Phenol, 4-[2-(1,1-dimethylethyl)-5-phenyl-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 54551-65-4 CAPLUS
CN Oxazole, 5-(4-chlorophenyl)-2-(1,1-dimethylethyl)-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 54551-66-5 CAPLUS

CN Oxazole, 5-(2-chlorophenyl)-2-(1,1-dimethylethyl)-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 54551-67-6 CAPLUS
CN Oxazole, 5-(3-chlorophenyl)-2-(1,1-dimethylethyl)-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 54551-68-7 CAPLUS
CN Phenol, 4-[2-(1,1-dimethylethyl)-5-(4-methoxyphenyl)-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 54551-69-8 CAPLUS
CN Phenol, 4-[5-(3-chlorophenyl)-2-(1,1-dimethylethyl)-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 54551-70-1 CAPLUS
CN Phenol, 4-[2-(1,1-dimethylethyl)-5-(3-methylphenyl)-4-oxazolyl]- (9CI) (CA INDEX NAME)



RN 54551-81-4 CAPLUS
CN Oxazole, 5-(3-chlorophenyl)-4-(4-methoxyphenyl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 26 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1970:43563 CAPLUS
DOCUMENT NUMBER: 72:43563
TITLE: Reaction of α-acyloxyketones with ammonium acetate
AUTHOR(S): Strzybny, P. P. E.; Van Es, T.; Backeberg, O. G.
CORPORATE SOURCE: Univ. Witwatersrand, Johannesburg, S. Afr.
SOURCE: Journal of the South African Chemical Institute (1969), 22(3), 158-64
CODEN: JSACAT; ISSN: 0038-2078
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Preparation of a number of α-acyloxy ketones is described. Reaction of these compds. with NH4OAc in AcOH forms oxazoles, imidazoles, and occasionally, amides. The following α-acyloxy ketones were prepared from the appropriate benzoin and Ac2O or the appropriate acid chloride in pyridine. The solution was heated 0.5 hr on a water bath and poured into water (compound, m.p., and % yield given): benzoin acetate, 82-4°, 85; benzoin benzoate, 1 28-9°, 90; benzoin p-methoxybenzoate, 105-6°, 79; benzoin p-nitrobenzoate, 126-7°, 92; 4'-nitrobenzoin acetate, 129-30°, 59; 5-methoxybenzoin acetate, 75-6°, 88; 4-methoxybenzoin benzoate, 117-19°, 93; 4-methoxybenzoin p-methoxybenzoate, 108-9°, 72; 4-methoxybenzoin p-nitrobenzoate, 116-17°, 92; 4'-methoxybenzoin benzoate, 124-5°, 14; anisoin acetate, 100-1°, 79; anisoin benzoate, 93-4°, 80; anisoin p-methoxybenzoate, 134-5°, 71; anisoin p-nitrobenzoate, 121-2°, 86; 4,4'-dibromobenzoin acetate, 87-9°, 92; 4,4'-dibromobenzoin p-methoxybenzoate, 145-6°, 81; 4,4'-dibromobenzoin p-nitrobenzoate, 99-101°, 91; acetoin p-nitrobenzoate, 69-70°, 78; ω-hydroxyacetophenone acetate, 168-72°, 67. The following acyloxy ketones were prepared from the corresponding α-bromo ketone and the Na salt of the appropriate acid in EtOH. High yields of these compds. were also obtained in refluxing the α-bromo ketone with excess Na salt in dimethylformamide for 1 hr (compds., m.p., and % yield given): ω-hydroxyacetophenone benzoate, 124-6°, 75; ω-hydroxyacetophenone p-methoxybenzoate, 137-8°, 67; ω-hydroxyacetophenone p-nitrobenzoate, 128-9°, 52; α-hydroxypropiophe-none acetate, 185° (4 mm), 79; α-hydroxypropiophenone p-nitrobenzoate, 124-5°, 97; α-hydroxypropiophenone o-nitrobenzoate, 80-1°, 48; α-hydroxypropiophenone p-methoxybenzoate, 109-10°, 88; α-hydroxybutyrophenone benzoate, 62-3°, 71; α-hydroxybutyrophenone p-nitrobenzoate, 61-2°, 68. The α-acyloxy ketone (0.02 mole), 0.1 mole NH4Ac, and 50 ml AcOH was refluxed 1 hr after which the reaction mixture was poured into water. The oxazoles which separated were crystallized from a suitable solvent while the aqueous filtrate, when made alkaline with NH3, gave the imidazole. In the case of esters of ω-hydroxyacetophenone no reaction occurred unless the quantity of NH4OAc was increased considerably, and by using 0. 06 mole, effective reaction occurred. Benzoin benzoate (1.0 g) and 5.0 g NH4Ac was heated at 140° 2 hr and poured into water to give 26% 2,4,5-triphenyloxazole. The aqueous solution made alkaline gave 74% 2,4,5-triphenylimidazole. The same 2 compds. in BuOH gave after 1 hr refluxing oxazole and N-desylbenzamide, m. 141-2°. Removal of oxazole and amide gave 13.5% 2,4,5-triphenylimidazole by making the mother liquor alkaline Benzoin acetate and benzoin p-nitrobenzoate gave no amide but only the corresponding oxazoles and imidazoles. The yield of imidazole

depends on the structure of the α-acyloxy ketone, but no general rule could be deduced from the results.

IT **25205-80-5P 25220-22-8P 25220-23-9P 25220-24-0P 25220-25-1P 25220-26-2P 25220-27-3P 25220-28-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 25205-80-5 CAPLUS
CN Oxazole, 4,5-bis(4-methoxyphenyl)-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 25220-22-8 CAPLUS
CN Oxazole, 4-(4-methoxyphenyl)-2,5-diphenyl- (9CI) (CA INDEX NAME)



RN 25220-23-9 CAPLUS
CN Oxazole, 2,4-bis(4-methoxyphenyl)-5-phenyl- (9CI) (CA INDEX NAME)



RN 25220-24-0 CAPLUS
CN Oxazole, 4-(p-methoxyphenyl)-2-(p-nitrophenyl)-5-phenyl- (8CI) (CA INDEX NAME)



RN 25220-25-1 CAPLUS
CN Oxazole, 5-(p-methoxyphenyl)-2,4-diphenyl- (8CI) (CA INDEX NAME)



RN 25220-26-2 CAPLUS
CN Oxazole, 4,5-bis(4-methoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 25220-27-3 CAPLUS
CN Oxazole, 4,5-bis(4-methoxyphenyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 25220-28-4 CAPLUS
CN Oxazole, tris(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


N
O
MeO
OMe
OMe

L10 ANSWER 33 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1974:146981 CAPLUS
DOCUMENT NUMBER: 80:146981
TITLE: Ethylenically unsaturated heterocyclics
INVENTOR(S): Siegrist, Adolf E.; Liechti, Peter; Maeder, Erwin; Guglielmetti, Leonardo; Meyer, Hans Rudolf; Weber, Kurt
PATENT ASSIGNEE(S): Ciba-Geigy A.-G.
SOURCE: Patentschrift (Switz.), 56 pp.
CODEN: SWXXAS
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CH 542212	A	19731115	CH 1966-13745	19660923
PRIORITY APPLN. INFO.:			CH 1966-13745 A	19660923

AB Two hundred twenty-five heterocyclic compds. containing styryl or substituted styryl groups were prepared and were used as fluorescent whitening agents for polyester fibers and were incorporated into polyester, polyamide, and polypropylene melts which were spun into fibers having good fluorescent whitening properties. Thus, 6-phenyl-2-p-tolylbenzoxazole was treated with PhCH:NHPh in DMF in the presence of KOCMe3 at 20-31.deg. to give fluorescent whitener I [6660-87-3]. Similarly fluorescent whitener (II) [16184-00-2] was prepared by condensation of 4-biphenylcarboxaldehyde anil with 1,4,5-triphenyl-2-p-tolylimidazole in DMF in the presence of KOH.

IT **16178-22-6P 16178-23-7P 16178-24-8P**
16178-25-9P 16178-26-0P
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of)

RN 16178-22-6 CAPLUS
CN Oxazole, 2-phenyl-4,5-bis[4-(2-phenylethenyl)phenyl]- (9CI) (CA INDEX NAME)



RN 16178-23-7 CAPLUS
CN Oxazole, 4,5-bis[4-(2-[1,1'-biphenyl]-4-ylethenyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 16178-24-8 CAPLUS
CN Oxazole, 4,5-bis[4-[2-(1-naphthalenyl)ethenyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 16178-25-9 CAPLUS
CN Oxazole, tris[4-(2-phenylethenyl)phenyl]- (9CI) (CA INDEX NAME)



RN 16178-26-0 CAPLUS
CN Oxazole, tris[4-(2-[1,1'-biphenyl]-4-ylethenyl)phenyl]- (9CI) (CA INDEX NAME)



IT **16112-18-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with benzylideneaniline derivs. in presence of base)
RN 16112-18-8 CAPLUS
CN Oxazole, tris(4-methylphenyl)- (9CI) (CA INDEX NAME)



IT **16112-17-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with benzylideneaniline derivs. in the presence of base)
RN 16112-17-7 CAPLUS
CN Oxazole, 4,5-bis(4-methylphenyl)-2-phenyl- (9CI) (CA INDEX NAME)


Ph
N
O
Me
Me

L10 ANSWER 34 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:526485 CAPLUS
DOCUMENT NUMBER: 79:126485
TITLE: Oxazole derivatives and their salts and esters
INVENTOR(S): Derible, Pierre H.; Taliani, Laurent
PATENT ASSIGNEE(S): Roussel-UCLAF
SOURCE: Fr. Demande, 27 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2156486	A1	19730601	FR 1971-38043	19711022
FR 2156486	B1	19751128		

PRIORITY APPLN. INFO.: FR 1971-38043 A 19711022
GI For diagram(s), see printed CA Issue.
AB The oxazole derivs. I (R = R1 = Ph, p-MeOC6H4, p-ClC6H4, R2 = H, X = O, S; R = p-ClC6H4, R1 = H, Me, R2 = H, X = O, S; R = R2 = H, R1 = p-ClC6H4, X = S; R = R1 = p-MeOC6H4, R2 = Me, X = O) were prepared Thus, 51% I (R = R1 = Ph, R2 = H, X = S) was obtained by treating HSCH2CO2Et with 2-chloro-4,5-diphenyloxazole and hydrolyzing the ester group. I are analgesics, antipyretics, and inflammation inhibitors. Thus, at 200 mg/kg orally they caused 18-53% inhibition of carrageenan edema in rats.
IT **40198-58-1P 49656-08-8P 49656-11-3P**
49656-12-4P 49656-26-0P 49656-27-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 40198-58-1 CAPLUS
CN Acetic acid, [[4,5-bis(4-methoxyphenyl)-2-oxazolyl]thio]- (9CI) (CA INDEX NAME)



RN 49656-08-8 CAPLUS
CN 2(3H)-Oxazolone, 4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 49656-11-3 CAPLUS
CN Acetic acid, [[4,5-bis(4-methoxyphenyl)-2-oxazolyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 49656-12-4 CAPLUS
CN Acetic acid, [[4,5-bis(4-methoxyphenyl)-2-oxazolyl]oxy]- (9CI) (CA INDEX NAME)



RN 49656-26-0 CAPLUS
CN Propanoic acid, 2-[[4,5-bis(4-methoxyphenyl)-2-oxazolyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 49656-27-1 CAPLUS
CN Propanoic acid, 2-[[4,5-bis(4-methoxyphenyl)-2-oxazolyl]oxy]- (9CI) (CA INDEX NAME)



IT **49656-06-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with mercaptoacetate)
RN 49656-06-6 CAPLUS
CN Oxazole, 2-chloro-4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 41 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1971:436005 CAPLUS
DOCUMENT NUMBER: 75:36005
TITLE: Antiinflammatory oxazoles
INVENTOR(S): Brown, Kevan
PATENT ASSIGNEE(S): John Wyeth and Brother Ltd.
SOURCE: U.S., 4 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3578671	A	19710511	US 1967-680990	19671106
PRIORITY APPLN. INFO.:			US 1967-680990 A	19671106

AB Diphenyloxazol-2-yl alkanoic acids, antiinflammatory and antiulcer agents, were prepared by reacting a keto ester with NH3 or by esterification of an α-hydroxy ketone with, e.g., an anhydride. For example, benzoin and succinic anhydride gave the benzoin H succinate which with NH4OAc-HOAc gave β-(4,5-diphenyloxazol-2-yl)propionic acid (I). Similarly prepared were 11 related compds., e.g., the di-p-methoxy derivative of I.

IT **18046-22-5P 24248-43-9P 24248-45-1P**
24248-53-1P 33002-79-8P 33002-84-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 18046-22-5 CAPLUS
CN 2-Oxazolepropanoic acid, 5-(4-chlorophenyl)-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 24248-43-9 CAPLUS
CN 2-Oxazolepropanoic acid, 4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 24248-45-1 CAPLUS
CN 2-Oxazolepropanoic acid, 4-(4-methoxyphenyl)-5-phenyl- (9CI) (CA INDEX NAME)



RN 24248-53-1 CAPLUS
CN 2-Oxazolepropionic acid, 4-(p-chlorophenyl)-5-(p-methoxyphenyl)- (8CI) (CA INDEX NAME)



RN 33002-79-8 CAPLUS
CN 2-Oxazolepropionic acid, 5-phenyl-4-p-tolyl- (8CI) (CA INDEX NAME)



RN 33002-84-5 CAPLUS
CN 2-Oxazolepropionic acid, 5-(p-chlorophenyl)-4-(2,4-dimethoxyphenyl)- (8CI) (CA INDEX NAME)


HO2C— CH2— CH2
N
O
OMe
OMe
Cl

L10 ANSWER 49 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1977:189783 CAPLUS
DOCUMENT NUMBER: 86:189783
TITLE: Photolytic closure of 4,5-diphenyloxazol-2-ones to phenanthro[9,10-d]oxazol-2-ones and an improved synthesis of benzoins
AUTHOR(S): Hakimelahi, Gholamhosein H.; Boyce, Charles B.; Kasmai, Hamid S.
CORPORATE SOURCE: Dep. Chem., Pahlavi Univ., Shiraz, Iran
SOURCE: Helvetica Chimica Acta (1977), 60(2), 342-7
CODEN: HCACAV; ISSN: 0018-019X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 86:189783
GI



I



II

AB Phenanthrooxazolones I (R = H, Ac, Me, PhCH2; R1 = H, Cl; R2 = H; R3, R4 = H, Me, MeO;R5 = H, MeO; R2R3, R4R5 = methylenedioxy) were prepared by photochem. ring closure of diphenyloxazolones II in MeOH containing CuCl2. II were prepared by cyclocondensation of H2NCO2Et with the benzoins 2,3,4-R1R2R3C6H2CH(OH)COC6H3R5R4-3,4, which were prepared by an improved benzoin condensation using aprotic solvents and (Me3C)4N+ CN- catalyst.

IT **49656-08-8P 62762-74-7P 62762-75-8P**
62762-78-1P 62762-79-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and benzylation of)

RN 49656-08-8 CAPLUS
CN 2(3H)-Oxazolone, 4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 62762-74-7 CAPLUS
CN 2(3H)-Oxazolone, 5-(4-methoxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 62762-75-8 CAPLUS
CN 2(3H)-Oxazolone, 4,5-bis(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 62762-78-1 CAPLUS
CN 2(3H)-Oxazolone, 5-(4-methylphenyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 62762-79-2 CAPLUS
CN 2(3H)-Oxazolone, 4-(3,4-dimethoxyphenyl)-5-phenyl- (9CI) (CA INDEX NAME)


H
N
O
O
Ph
OMe
OMe

L10 ANSWER 50 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1971:22814 CAPLUS
DOCUMENT NUMBER: 74:22814
TITLE: Oxazoles, and their pharmaceutical compositions
INVENTOR(S): Brown, Kevan
PATENT ASSIGNEE(S): John Wyeth and Brother Ltd.
SOURCE: Brit., 8 pp.
CODEN: BRXXAA
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1206403		19700923	GB	19661215

GI For diagram(s), see printed CA Issue.

AB The title compds. (I) show antiinflammatory properties in exptl. animals. Heating a mixture of 21.2 g benzoin and 10 g succinic anhydride at 120° for 6 hr gave 27 g benzoin hemisuccinate (II), m. 88.5-9.5° (aqueous Me2CO). Refluxing a mixture of 15 g II and 30 g NH4OAc in 100 ml AcOH for 1.5 hr gave 11.7 g I (R1 = CH2CH2CO2H, R2 = R3 = Ph) (II), m. 160.5-1.5° (MeOH). Similarly prepared were anisoin hemisuccinate (sticky foam); I (R1 = CH2CH2CO2H, R2 = R3 = 4-MeOC6H4), m. 81.5-84° (C6H6-petroleum ether); 4-methoxybenzoin hemisuccinate; I (R1 = CH2CH2CO2H, R2 = 4-MeOC6H4, R3 = Ph), m. 118-20°. Heating a mixture of 10.8 g 4'-chloro-4-methoxybenzoin hemisuccinate, 3.6 g urea, and 25 ml AcOH under reflux for 3 hr gave 6.7 g I (R1 = CH2CH2CO2H, R2 = 4-MeOC6H4, R3 = 4-ClC6H4), m. 130.5-2.5°. Cyclization of benzoin hemiglutarate with NH4OAc and AcOH gave 89% I [R1 = (CH2)3CO2H, R2 = R3 = Ph], m. 125-6°. I (R1 = CH2CH2CO2Et, R2 = R3 = Ph), m. 69.5-71° (EtOH) was prepared in 4.6 g yield by refluxing a mixture of 5 g II, 100 ml EtOH and 1 ml H2SO4 for 16 hr. Treatment of 2.5 g II in a mixture of 10 ml THF and 10 ml dioxane containing 0.85 ml Et3N with 1.23 g iso-BuO2CCl, stirring in ice for 0.5 hr and at room temperature for 1 hr then adding 1 ml NH4OH (d. 0.88) gave 1.7 g I (R1 = CH2CH2CONH2, R2 = R3 = Ph), m. 146-7° (EtOH). There were also prepared 4'-chlorobenzoin hemisuccinate; I (R1 = CH2CH2CO2H, R2 = Ph, R3 = 4-ClC6H4), m. 180-2°; 4'-methylbenzoin hemisuccinate; I (R1 = CH2CH2CO2H, R2 = Ph, R3 = 4-MeC6H4), m. 169-70°; 4-chlorobenzoin hemisuccinate; I (R1 = CH2CH2CO2H, R2 = 4-ClC6H4, R3 = Ph), m. 155-7°; 4-chloro-4'-methoxybenzoin; I (R1 = CH2CH2CO2H, R2 = 4-Cl-C6H4, R3 = 4-MeOC6H4), m. 126-8°. A mixture of 5.8 g II, 2.8 g Et3N, and 1.84 ml acetoxymethyl bromide in 50 ml DMF was kept at room temperature overnight to give 5 g I (R1 = CH2CH2CO2CH2OAc, R2 = R3 = Ph), m. 86-6.5°. Refluxing a mixture of 10 g Me phenacyl succinate (prepared from phenacyl Br and Na Me succinate in EtOH), 6 g urea, and 30 ml AcOH for 2 hr gave 5.4 g oily I (R1 = CH2CH2CO2H, R2 = Ph, R3 = H) (III). Refluxing the oil with 5 g KOH, 100 ml EtOH, and 10 ml H2O for 1 hr gave 1.63 g III, m. 115-17° (aqueous EtOH). A mixture of 5 g phenacylamine-HCl and 10 ml C5H5N was warmed and treated with 2 g MeO2CCH2CH2COCl to give 6.15 g oil which on leaving in concentrated H2SO4 for 4 hr gave 2.43 g I (R1 = CH2CH2CO2Me, R2 = H, R3 = Ph) hydrolyzed with KOH in EtOH at room temperature to 1.69 g I (R1 = CH2CH2CO2H, R2 = H, R3 = Ph), m. 148-9°. Capsules were prepared containing 125 mg II, 120 mg lactose and 5 mg Mg stearate.

IT **18046-22-5P 24248-43-9P 24248-45-1P**

24248-51-9P 24248-53-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 18046-22-5 CAPLUS
CN 2-Oxazolepropanoic acid, 5-(4-chlorophenyl)-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 24248-43-9 CAPLUS
CN 2-Oxazolepropanoic acid, 4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 24248-45-1 CAPLUS
CN 2-Oxazolepropanoic acid, 4-(4-methoxyphenyl)-5-phenyl- (9CI) (CA INDEX NAME)



RN 24248-51-9 CAPLUS
CN 2-Oxazolepropionic acid, 4-phenyl-5-p-tolyl- (8CI) (CA INDEX NAME)



RN 24248-53-1 CAPLUS
CN 2-Oxazolepropionic acid, 4-(p-chlorophenyl)-5-(p-methoxyphenyl)- (8CI) (CA INDEX NAME)



L10 ANSWER 59 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1991:471469 CAPLUS
DOCUMENT NUMBER: 115:71469
TITLE: Reaction of [alkyl(aryl)carbonylamino]hydroxymethyl aryl ketones with aromatic hydrocarbons
AUTHOR(S): Bal'on, Ya. G.; Smirnov, V. A.
CORPORATE SOURCE: Kiev. Nauchno-Issled. Inst. Endokrinol. Obmena Veshchestv, Kiev, USSR
SOURCE: Zhurnal Organicheskoi Khimii (1990), 26(9), 1983-7
CODEN: ZORKAE; ISSN: 0514-7492
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 115:71469
GI



II

AB The treatment of ArCOCHO (Ar = Ph, p-BrC6H4) with H2NCOR (R = alkyl, CCl3, substituted Ph, 3-pyridyl) gives ArCOCH(OH)NHCOR (I). The reactions of I with Ar1H (Ar1 = substituted Ph) give oxazoles II (X = O) or imidazoles II (X = NH), depending on the reaction conditions. II (X = O) can be converted into II (X = NH) by treatment with AcONH4.

IT **26107-35-7P 135120-40-0P 135120-42-2P 135120-43-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and recyclization of, with ammonium acetate)

RN 26107-35-7 CAPLUS
CN Oxazole, 4-(4-methylphenyl)-2,5-diphenyl- (9CI) (CA INDEX NAME)



RN 135120-40-0 CAPLUS
CN Oxazole, 2-ethyl-4-(4-methylphenyl)-5-phenyl- (9CI) (CA INDEX NAME)



RN 135120-42-2 CAPLUS
CN Oxazole, 5-(4-bromophenyl)-4-(4-methylphenyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 135120-43-3 CAPLUS
CN Oxazole, 5-(4-bromophenyl)-4-(2,5-dimethylphenyl)-2-phenyl- (9CI) (CA INDEX NAME)



L10 ANSWER 76 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:544101 CAPLUS
DOCUMENT NUMBER: 121:144101
TITLE: Polyimide-based electrooptic materials
AUTHOR(S): Cahill, P. A.; Seager, C. H.; Meinhardt, M. B.; Beuhler, A. J.; Wargowski, D. A.; Singer, K. D.; Kowalczyk, T. C.; Kosc, T. Z.
CORPORATE SOURCE: Dep. 1811, Sandia Natl. Lab., Albuquerque, NM, 87185, USA
SOURCE: Proceedings of SPIE-The International Society for Optical Engineering (1993), 2025(Nonlinear Optical Properties of Organic Materials VI), 48-55
CODEN: PSISDG; ISSN: 0277-786X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The properties of new, high temperature optical materials based on dye-doped Ultradel® 9000D1 polyimides are presented. Ultradel 9000D is a soluble, pre-imidized, fluorinated polymer with properties optimized for integrated optical applications. When thermally of photochem. cross-linked, it has a Tg approaching 400°C and retains excellent optical transparency as measured by both waveguide loss spectroscopy (WLS) and photothermal deflection spectroscopy (PDS). The agreement between WLS and PDS data indicates that losses in polyimides are due to absorption, not scattering. Two thermally stable, donor-acceptor oxazole-based dyes were designed, synthesized, and doped into the polyimide at concns. up to 25 percent by weight The Tg of the doped polymers decreased from the neat polymer, but remained above 300°C. The effects of doping on the dielec. constant, refractive index, and coefficient of thermal expansion of the polyimide are presented. The oxazoles also photobleach and thereby provide an addnl. means of photodefining waveguides in these materials.

IT **25205-80-5 157189-20-3 157189-22-5**
RL: PRP (Properties)
(electrooptic materials from polyimides doped with)

RN 25205-80-5 CAPLUS
CN Oxazole, 4,5-bis(4-methoxyphenyl)-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 157189-20-3 CAPLUS
CN Benzonitrile, 4-[4,5-bis(4-methoxyphenyl)-2-oxazolyl]- (9CI) (CA INDEX NAME)



RN 157189-22-5 CAPLUS
CN Oxazole, 4,5-bis(4-methoxyphenyl)-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 78 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1988:160931 CAPLUS
DOCUMENT NUMBER: 108:160931
TITLE: 2-Aminooxazoles as potential hydrogen-bonding virucides. Part 1. N-Unsubstituted and N-substituted 2-aminooxazoles
AUTHOR(S): Ulbricht, H.
CORPORATE SOURCE: Zentralinst. Mikrobiol. Exp. Ther., Akad. Wiss. DDR, Jena, DDR-6900, Ger. Dem. Rep.
SOURCE: Pharmazie (1987), 42(9), 598-601
CODEN: PHARAT; ISSN: 0031-7144
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 108:160931
GI



I

AB A group of 39 title derivs. was prepared according to previously reported methods. The antiviral activity of the compds. was tested in vitro by inhibition of plaque formation in cell cultures infected with several RNA and DNA viruses. Of the N-unsubstituted derivs., only one (I, R1 = R2 = Ph; R3 = R4 = H) inhibited Coxsackie B1-virus. Among the N-substituted derivs., 6 compds. [I, R1 = R2 = Ph, Pr, C6H4CH2OH-4; R3 = H, CH2CH2OH; R4 = CHMe2, CH2CH2OH, CH2CH2CO2Me, C(:NH)NH2] had in vitro antiviral effects. I [R1 = R2 = Ph; R3 = H; R4 = C(C:NH)NH2] was the most effective compound The N-substituted derivs. are more active and their activity rise with introduction of hydrophilic NR3R4 substituents. The hydrophobic R1 = R2 = Ph substitution in several of the active derivs. apparently has a steric significance for the biol. activity; the size of the other R1 and R2 substituents is similar to Ph.

IT **113853-19-3P 113853-20-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antiviral activity of)
RN 113853-19-3 CAPLUS
CN Oxazole, 4,5-bis(4-methoxyphenyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 113853-20-6 CAPLUS
CN Ethanol, 2,2'-[[4,5-bis(4-methoxyphenyl)-2-oxazolyl]imino]bis- (9CI) (CA INDEX NAME)



IT **49656-06-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with amines)
RN 49656-06-6 CAPLUS
CN Oxazole, 2-chloro-4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 100 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:279560 CAPLUS
DOCUMENT NUMBER: 124:327958
TITLE: Modifications of organic electroluminescent devices for display backlight applications
AUTHOR(S): Jordan, R. H.; Dodabalapur, A.; Rothberg, L. J.; Slusher, R. E.; Strukelj, M.; Miller, T. M.
CORPORATE SOURCE: At&T Bell Laboratories, Murray Hill, NJ, 07974, USA
SOURCE: Proceedings - Electrochemical Society (1996), 95-25(Advanced Luminescent Materials), 403-412
CODEN: PESODO; ISSN: 0161-6374
PUBLISHER: Electrochemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Two variations on evaporated organic electroluminescent devices are reported. Green thin film microcavity organic electroluminescent devices are described which have enhanced spatially integrated (.apprx.2) and forward (>3) surface-emitted intensity. Enhancement is obtained by optimizing cavity mode parameters with respect to the electroluminescent emitter. Also, multilayer organic electroluminescent devices are described which employ a blue-emitting species as a layer sandwiched between the hole transporter bis(triphenyl)diamine and the light emitting electron transporter tris(8-hydroxyquinoline)aluminum to obtain bright (.apprx.5000 cd/m2 at 580 mA/cm2) efficient (0.5 lm/W) white emission.

IT **25220-27-3**, 2-Phenyl-4,5-bis(4-methoxyphenyl)-1,3-oxazole
176678-52-7
RL: DEV (Device component use); USES (Uses)
(modifications of organic electroluminescent devices for display backlight applications)

RN 25220-27-3 CAPLUS
CN Oxazole, 4,5-bis(4-methoxyphenyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 176678-52-7 CAPLUS
CN Oxazole, 4,5-bis(4-methoxyphenyl)-2-(1-naphthalenyl)- (9CI) (CA INDEX NAME)


OMe
OMe
N
O

L10 ANSWER 105 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1984:406947 CAPLUS
DOCUMENT NUMBER: 101:6947
TITLE: Synthesis of α,β-epoxyacyl azides and their rearrangement to epoxy isocyanates and 3- and 4-oxazolin-2-ones
AUTHOR(S): Lemmens, Jacques M.; Blommerde, Willem W. J. M.; Thijs, Lambertus; Zwanenburg, Binne
CORPORATE SOURCE: Dep. Org. Chem., Univ. Nijmegen, Nijmegen, 6525 ED, Neth.
SOURCE: Journal of Organic Chemistry (1984), 49(12), 2231-5
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 101:6947
GI



AB The conversion of α,β-epoxy carboxylates I [R1 = Ph, 4-O2NC6H4, 4-MeC6H4, Me; R2 = H, Ph, Me; R3 = H, Ph, Me, 4-MeC6H4, 4-MeOC6H4; R1R3 = (CH2)5, R2 = H; R1CR2 = adamantane moiety, R3 = H; R1R2 = (CH2)5, (CH2)4, R3 = Me, H] into α,β-epoxyacyl azides II proceeds either via reaction of the mixed anhydrides III with NaN3 or via reaction of epoxyacyl chlorides IV with HN3--pyridine. The latter method is preferred. The azides II undergo a smooth thermal Curtius rearrangement to give 4-oxazolin-2-ones V for the substrates II (R2 = H) having a H atom at Cβ. Monitoring this reaction by means of IR shows that the epoxy isocyanates VI are intermediates. Intramol. ring expansion of VI then leads to 3-oxazolin-2-ones VII that tautomerize to the 4-isomers V. Epoxyacyl azides II, having no H atom at Cβ, produce 3-oxazolin-2-ones VII as a proton shift is not possible. The products VII [R1CR2 = adamantane moiety, R3 = H; R1R2 = (CH2)5, R3 = Me] rapidly add water at the imine bond to give oxazolidin-2-ones VIII. Epoxy isocyanate VI [R1R2 = (CH2)5, R3 = H] is reasonably stable in solution; reaction with MeOH affords urethane IX.
IT **62762-78-1P 89849-09-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 62762-78-1 CAPLUS
CN 2(3H)-Oxazolone, 5-(4-methylphenyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 89849-09-2 CAPLUS
CN 2(3H)-Oxazolone, 4-(4-methylphenyl)-5-phenyl- (9CI) (CA INDEX NAME)



L10 ANSWER 111 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1962:462705 CAPLUS
DOCUMENT NUMBER: 57:62705
ORIGINAL REFERENCE NO.: 57:12457f-i,12458a
TITLE: A new method for the preparation of 4,5-disubstituted 4-oxazoline-2-thiones
AUTHOR(S): Willems, J. F.; Vandenberghe, A.
SOURCE: Bulletin des Societes Chimiques Belges (1961), 70, 745-57
CODEN: BSCBAG; ISSN: 0037-9646
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
GI For diagram(s), see printed CA Issue.

AB 4-Oxazolin-2-ones (I), prepared by condensation of urethans and carbamyl chlorides with R1COCHR2OH (II) were converted into Δ4-oxazoline-2-thiones (III) with P2S5. Isothiocyanates and thiourethans failed to condense with II (Gompper, CA 51, 5754g). With benzoin, PhNCS gave benzanilide, phenylthiourethan, and N,N'-diphenylthiourea. In the presence of thiocyanic acid or its salts, II gave analogs of III. Condensation was affected in boiling EtOH for 24 hrs. in the presence of 1.5 mole HSCN or KSCN and HCl and 1 mole of II. The unreacted II was removed by treatment with NaOH, which dissolved Ill but not II. The alkali solution gave HI on acidification with HOAc. The following III were prepared (R1, R2, m.p. given): Me, Me, 137° (water); Pr, Pr, 128-40° (decomposition); Ph, H, 170° (water); Ph, Ph, 260° (MeOCH2CH2OH); p-Me2NC6H4, Ph, 236° (ETOH); p-anisyl, Ph, 175° (EtOH-H2O); p-anisyl, p-anisyl, 204° (ETOH); (R1R2 =) (CH2)4, 154° (water). Use of H2SO4 instead of HCl led to 2-alkylthiooxazoles due to alkylation by the alkyl sulfates formed. When R1 and R2 were different, two isomers were obtained, p-Methoxybenzoin gave IV (R1 = Ph,R2 = p-anisyl), m. 229°. p-Anisoin gave IV (R1 = R2 = p-anisyl), m. 187°. IV (R1 = p-anisyl, R2 = Ph), m. 205° was prepared from p-methoxyphenyl α-bromobenzyl ketone, m. 97-8°, by way of the α-cyanato derivative, m. 92°, and cyclization with concentrated HCl. With NH4CNS alone, V were formed. V (R1 = R2 = Ph), from benzoin, m. 260°. Infrared spectral data and spectra were given (G. and Herlinger, CA 51,11854e).

IT **6670-17-3**, 4-Oxazoline-2-thione, 4-(p-methoxyphenyl)-5-phenyl-
84589-36-6, 4-Oxazoline-2-thione, 4,5-bis(p-methoxyphenyl)-
(preparation of)

RN 6670-17-3 CAPLUS
CN 4-Oxazoline-2-thione, 4-(p-methoxyphenyl)-5-phenyl- (7CI, 8CI) (CA INDEX NAME)



RN 84589-36-6 CAPLUS
CN 2(3H)-Oxazolethione, 4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


H
N
S
O
OMe
OMe

L10 ANSWER 114 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1957:29820 CAPLUS
DOCUMENT NUMBER: 51:29820
ORIGINAL REFERENCE NO.: 51:5754g-i,5755a-i,5756a-c
TITLE: The azole series. I. Preparation and properties of 2-oxazolones
AUTHOR(S): Gompper, Rudolf
CORPORATE SOURCE: Tech. Hochschule, Stuttgart, Germany
SOURCE: Chemische Berichte (1956), 89, 1748-62
CODEN: CHBEAM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB Refluxing 10 g. benzoin with 25 g. Me2NCOCl 4 hrs. on a water bath and distilling the chloride yield 90% benzoin N,N-dimethylcarbamate (I), m. 156°. Treating 37 g. PhCOCH2NHCO2Et with 4.5 g. Na in EtOH 15 hrs. at 20° and adding H2O give α-carbethoxyamino-N-phenacylbenzoylacetamide (II), m. 286° (decomposition). N-Unsubstituted 2-oxazolones are prepared: a, by heating an α-hydroxyketone (III) with excess urethan (IV) in a ratio of 1:5-10 with slow distillation and pouring the mixture into H2O; b, by refluxing III with excess IV in HCONMe2 in the presence of a small amount of C5H5N; c, by refluxing III and IV in AcOH in the presence of concentrated H2SO4; da, by adding a carbamide acid chloride and C5H5N to III in C6H6 or Et2O with cooling, keeping the mixture several hrs. at 20°, distilling the solvent, and refluxing the residue 1 hr. with 5:1 EtOH-H2SO4; db, treating the mixture without removal of the solvent 2-4 hrs. with polyphosphoric acid, pouring the mixture into H2O, and making the solution alkaline with NaOH; e, heating a N,N-dimethylcarbamide acid ester of III with a mixture of NH4OAc and AcOH. Refluxing 33 g. propionoin (V) and 81 g. IV 15 hrs. in 70 cc. HCONMe2 gives 37% 4,5-diethyl-2-oxazolone, b0.01 135-6°, m. 73°, which is also obtained in 40% yield when 38.7 g. V and 27 g. H2NCOCl in 500 cc. C6H6 are kept at 20°, the mixture is poured into H2O, adjusted to pH 8, extracted with Et2O, and the residue of the Et2O is fractionally distilled Treating 28 g. butyroin and 174 g. IV 6 hrs. according to a yields 41% 4,5-dipropyl-2-oxazolone (VI), b0.05 150°, m. 220°; according to b (15 hrs. reflux), 46% VI; or according to d, from 53 g. butyroin and 44 g. H2NCOCl in 400 cc. C6H6, 71% VI. 4,5-Diisopropyl-2-oxazolone, b, from 29 g. isobutyroin (VII) and 80 g. IV in 100 cc. HCONMe2, 46%, b0.02 128-33°, platelets, m. 128°; da, from 18.5 g. VII and 10.3 g. H2NCOCl in 350 cc. C6H6, 58%, m. 136°. The following addnl. substituted 2-oxazolones are prepared: 4,5-di-Bu, da, 47%, b0.01 166-7°; 4,5-di-Me2CHCH2, da, 64%, b0.2 172-4°; 4,5-di-Am, da, 17%, b0.02 160-2°; 4,5-di-C6H13, da, 19%, b0.02 162°; 4,5-di-C7H15, da, 50%, b0.005 167°; 4,5-di-C9H19, da, 41%, b0.02 220-2°; 5-Et, 4-Ph, da, 49%, b0.005 134-44°, m. 128°; 5-Pr homolog, da, 94%, b0.01 180-5°, m. 135°; 5-Bu homolog, db, 41% b0.01 186°; 5-C8H17 homolog, db, 44%, b0.01 193°; 4,5-di-Ph (VIII), a, 91%, b (6 hrs.), 93%, c (3 hrs.), 51%, da, 84%, e (6 hrs.), 95%, shiny needles, m. 211°; 5-phenyl-4-(p-methoxyphenyl), da, 71%, m. 212°; 4,5-bis(3,4,5-trimethoxyphenyl), b (5 hrs.), 75%, m. 214-15°; 4,5-bis(p-chlorophenyl), b (8 hrs.), 57%, m. 195°; 5-phenyl-4-(p-dimethylaminophenyl) (IX), from 75 g. p-dimethylaminobenzoin (X) and 15 g. IV, a (5 hrs.), 42%, m. 205° (decomposition); p-di-Et homolog, from 8.5 g. p-diethylaminobenzoin and 21 g. IV, a, 43%, m. 208° (decomposition); 3,5-di-(2-pyridyl), from 11 g. α-pyridoin and 22 g. IV, b (16 hrs.), 41%, shiny deep red needles, m. 219°; 4,5-tetramethylene-2-imidazolone, from 20 g. cyclohexanolone and 90 g. IV,

b (30 hrs.), 46%, m. 346°. Methylation of 9 (or 9.6) g. VI in 100 cc. MeOH with CH2N2 (or in aqueous Me2CO at pH 8-9 with Me2SO4) yields 51% (or 68%) 3-methyl-VI, b0.01 110-14°; methylation of 11 (or 5) g. VIII (or 4 g. acetyl-VIII) in 300 cc. N NaOH and Me2CO (or in 20 or 50 cc. MeOH) with 19 g. Me2SO4 and 100 cc. N NaOH (or excess CH2N2) at 40° and 2 hrs. at 100° gives 90% (94 or 78%) 3-methyl-VIII, b0.04 195-215°, needles, m. 96°. Refluxing 5 g. VIII and 6 g. Ag2O 8 hrs. in 12 g. MeI gives 62% 2-methoxy-VIII, b0.01 125-42°, and 0.9 g. 3-methyl-VIII, b0.01 160-72°. Adding 12 g. PhCH2Cl dropwise to 9 g. VIII in 100 cc. N NaOH and 100 cc. Me2CO at 40-50° with stirring, keeping the mixture 3 hrs., diluting it with H2O, and extracting with Et2O give 41% 3-benzyl-VIII, m. 100°. Refluxing 30 g. VI 3 hrs. with 14 g. C5H5N and 150 cc. Ac2O yields 64% 4,5-dipropyl-3-acetyl-2-oxazolone, b0.02 86-7°, b0.002 70°; 3-acetyl-VIII, 85%, m. 139°, is readily saponified on treatment with NH4OH; 3-chloroacetyl-VIII, 91%, m. 155°; 3-benzoyl-VIII, 67%, m. 178°; 3-acetyl-IX, 55%, needles, m. 147°. Treating 23 g. V with 23 g. PhNCO and a few drops of C5H5N gave 42% propionoin carbanilate, m. 121°, which (13.7 g.), refluxed with 80 cc. Ac2O, yields 64% 4,5-diethyl-3-phenyl-2-oxazolone, m. 96.5°; butyroin carbanilate, 67%, m. 132°; 4,5-dipropyl-3-phenyl-2-oxazolone, 84%, m. 50.5°. Warming 10 g. butyroin and 10 g. PhCH2NCO with a few drops of C5H5N 2 hrs. on a water bath gives 88% butyroin N-benzylcarbamate, m. 133-4°; 4,5-dipropyl-3-benzyl-2-oxazolone b0.001 148-56°, m. about 40°. Refluxing 57.5 g. butyroin, 35.2 g. p-C6H4(NCO)2, and 1 cc. C5H5N 4 hrs. in 140 cc. C6H6 yields 81% N,N'-p-phenylene-bis(carbamidoacid butyroin ester), m. 181°, which (54 g.), refluxed 2 hrs. with 300 cc. EtOH and 50 cc. concentrated H2SO4, gives 91% 1,4-bis(4,5-dipropyl-2-oxazolone-3-yl)benzene, m. 132°. Refluxing 34.5 g. valeroin (XI), 27.5 g. C6H11NCO, and 1 cc. C5H5N 6 hrs. in 100 cc. C6H6, distilling the C6H6, and refluxing the residue 1 hr. in 200 cc. EtOH and 50 cc. concentrated H2SO4 yield 40% 4,5-dibutyl-3-cyclohexyl-2-oxazolone, b0.01 115-19°; similarly, 34 g. XI, 24 g. PhNCO, and some C5H5N 1 day at 20° and 1 hr. at 100° give 46% 4,5-dibutyl-3-phenyl-2-oxazolone, b0.005 142-6°. Refluxing 50 g. PhCOCH(OH)Et, 58 g. PhNCO, and 1 cc. C5H5N in 100 cc. C6H6 3 hrs. gives 50% α-hydroxybutyrophenone carbanilate, fine silky needles, m. 164°, which (41 g.), refluxed 3 hrs. in 160 g. AcOH, gives 91% 5-ethyl-3,4-diphenyl-2-oxazolone, cubes, m. 121°. Benzoin and PhNCO via the benzoin carbanilate yield 90% 3,4,5-triphenyl-2-oxazolone, m. 211°, which is also obtained in 76% yield when 15 g. benzoin, 57 g. PhNHCO2Et, and 2 cc. C5H5N in 150 cc. HCONMe2 are refluxed 12 hrs., or in 10% yield when 14 g. BzCl is added dropwise to 7 g. NaN3 in 150 cc. HCONMe2, then 20 g. benzoin and 0.5 cc. C5H5N added, and the mixt heated 2 hrs. at 50°. Heating 10 g. benzoin and 6.6 g PhCH2NCO 0.5 hr. at 110-20° yields 50% benzoin N-benzylcarbamate, m. 188°, which (6.6 g.), refluxed 2 hrs. in 150 cc. AcOH, gives 83% 3-benzyl-VIII, m. 100°. Refluxing 7 g. benzoin and 35 g. 2-C10H7NHCO2Et in 100 cc. HCONMe2 20 hrs. yields 52% 4,5-diphenyl-3-β-naphthyl-2-oxazolone, m. 195-6°. Refluxing 20 g. p-methoxybenzoin and 12 g. PhNCO 2 hrs. in 150 cc. C6H6 gives 97% p-methoxybenzoin carbanilate, m. 209°, which (16 g.) refluxed 2 hrs. with 150 cc. EtOH and 30 cc. concentrated H2SO4, gives 85% 3,5-diphenyl-4-(p-methoxyphenyl)-2-oxazolone, m. 161°. Refluxing 23 g. X and 21 g. PhNCO 1 hr. in 150 cc. C6H6 gives 91% p-dimethylaminobenzoin carbanilate, m. 211°, which (16 g.), refluxed in EtOH and concentrated H2SO4, yields 85% 3,5-diphenyl-4-(p-dimethylaminophenyl)-2-oxazolone, m. 245°. Refluxing 169 g. PhCOCHBrEt 12 hrs. in 133 g. H2O and 375 g. HCONMe2 gives 75%

PhCOCH(OH)Et, b12 131.5-2.5°; PhCOCHBrPr, refluxed 20 hrs. in 250 cc. HCONMe2 and 90 g. H2O, gives 80% PhCOCH(OH)Pr, b0.05 80°; PhCOCH(OH)Bu, 67%, b0.01 84°; PhCOCH(OH)C8H17, 78%, b0.01 115°.

IT **101274-25-3**, 4-Oxazolin-2-one, 4-(p-methoxyphenyl)-5-phenyl-
102449-88-7, 4-Oxazolin-2-one, 4,5-bis(3,4,5-trimethoxyphenyl)-
(preparation of)

RN 101274-25-3 CAPLUS

CN 2(3H)-Oxazolone, 4-(4-methoxyphenyl)-5-phenyl- (9CI) (CA INDEX NAME)



RN 102449-88-7 CAPLUS

CN 4-Oxazolin-2-one, 4,5-bis(3,4,5-trimethoxyphenyl)- (6CI) (CA INDEX NAME)



L10 ANSWER 142 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:651571 CAPLUS
DOCUMENT NUMBER: 127:338911
TITLE: Light amplification in organic thin films using cascade energy transfer
AUTHOR(S): Berggren, M.; Dodabalapur, A.; Slusher, R. E.; Bao, Z.
CORPORATE SOURCE: Bell Lab., Lucent Technologies, Murray Hill, NJ, 07974, USA
SOURCE: Nature (London) (1997), 389(6650), 466-469
CODEN: NATUAS; ISSN: 0028-0836
PUBLISHER: Macmillan Magazines
DOCUMENT TYPE: Journal
LANGUAGE: English

AB There is currently renewed interest in the development of lasers using solid-state organic and polymeric materials as the gain media. These materials have a number of properties that make them good candidates for such applications-for example, emission bands that are displaced (via a Stokes shift) from absorption bands, and the ease with which the emitting species can be embedded in a suitable host material. But despite these advantages, the threshold power densities required for light amplification that are reported so far have been high. Here we describe an approach, based on energy transfer between mol. species, than can lower the threshold for stimulated emission and laser action while improving markedly the waveguiding properties of the active material. In our materials, and initial mol. excited state is generated in the host compound by absorption of light; this state is then resonantly and non-radiatively transferred down in energy (through one or more steps) between suitably matched dye mols. dispersed in the host, so ensuring that the absorption losses at the final emission wavelengths are very small. Such composite gain media provide broad tunability of the emission wavelength, and also decouple the optical emission properties from the transport properties, so providing greater flexibility for the design of future elec. driven device structures.

IT **178761-59-6**
RL: DEV (Device component use); PRP (Properties); USES (Uses)
(optical amplifier using DCM II doped vacuum sublimed film)

RN 178761-59-6 CAPLUS
CN Oxazole, 4,5-bis(4-methoxyphenyl)-2-(2-naphthalenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 177 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1982:492274 CAPLUS
DOCUMENT NUMBER: 97:92274
TITLE: Diarylimidazole compounds, pharmaceutical drugs containing them, and their use
INVENTOR(S): Sallmann, Alfred
PATENT ASSIGNEE(S): Ciba-Geigy A.-G. , Switz.
SOURCE: Eur. Pat. Appl., 78 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 46451	A2	19820224	EP 1981-810329	19810813
EP 46451	A3	19820421		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
FI 8102536	A	19820220	FI 1981-2536	19810817
ES 504787	A1	19831001	ES 1981-504787	19810817
IL 63595	A1	19850430	IL 1981-63595	19810817
DK 8103660	A	19820220	DK 1981-3660	19810818
NO 8102790	A	19820222	NO 1981-2790	19810818
AU 8174278	A1	19820225	AU 1981-74278	19810818
ZA 8105684	A	19820825	ZA 1981-5684	19810818
DD 201788	A5	19830810	DD 1981-232649	19810818
JP 57070873	A2	19820501	JP 1981-128833	19810819
ES 514478	A1	19830501	ES 1982-514478	19820728
ES 514479	A1	19830501	ES 1982-514479	19820728
ES 514480	A1	19830501	ES 1982-514480	19820728
ES 514481	A1	19830501	ES 1982-514481	19820728
ES 514482	A1	19830501	ES 1982-514482	19820728
ES 522922	A1	19850301	ES 1983-522922	19830601
ES 522923	A1	19850401	ES 1983-522923	19830601
ES 522924	A1	19850401	ES 1983-522924	19830601
ES 522925	A1	19850401	ES 1983-522925	19830601
ES 522921	A1	19850916	ES 1983-522921	19830601

PRIORITY APPLN. INFO.: CH 1980-6255 A 19800819
GI



AB Imidazoles I [R1, R2 independently = carbocyclic aryl and (or) heteroaryl; R3 = ZZ1R4 [Z = hydrocarbondiyl, Z1 = O, SOn (n = 0-2), R4 = (un)substituted hydrocarbyl or H when n = 0]] and their salts, useful as external inflammation inhibitors, sunscreens, antithrombotics, and anti-Herpes agents (no data), were prepared by many methods. Successively

treating H2SO4 with MeSCH2CN, then Me2C(OH)CH2CH(OH)Me at 0-5° 4.5 h, C-methylating dihydrooxazine II (R4R4 = bond, R5 = H) with BuLi, then MeI, reducing dihydro oxazine II (R4R4 = bond, R5 = Me) with NaBH4, and cyclizing tetrahydrooxazine II (R4 = H, R5 = Me) with 1-phenyl-2-(3-pyridyl)glyoxal and NH4OAc in AcOH gave pyridylimidazole III.

IT **82258-07-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and cyclization of, with ammonia)

RN 82258-07-9 CAPLUS

CN Oxazole, 4,5-bis(4-methoxyphenyl)-2-[(methylthio)methyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 179 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1981:192195 CAPLUS
DOCUMENT NUMBER: 94:192195
TITLE: Cyclization reactions of nitriles. I. Synthesis of 2-amino-4,5-diaryl- and diheteryloxazoles
AUTHOR(S): Sharanin, Yu. A.
CORPORATE SOURCE: Voroshilovgrad. Gos. Pedagog. Inst., Voroshilovgrad, USSR
SOURCE: Zhurnal Organicheskoi Khimii (1980), 16(10), 2185-8
CODEN: ZORKAE; ISSN: 0514-7492
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 94:192195
GI



I

AB The title oxazoles I (R = Ph, 4-MeOC6H4, 2-furyl) were obtained in 46-95% yield by treatment of RCHR1COR (R1 = OH, Br, OAc) with cyanamide.

IT **77151-48-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 77151-48-5 CAPLUS
CN 2-Oxazolamine, 4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 180 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1980:215427 CAPLUS
DOCUMENT NUMBER: 92:215427
TITLE: Aminooxazole derivatives
INVENTOR(S): Harrison, Roger Garrick; Simmonds, Robin George
PATENT ASSIGNEE(S): Lilly Industries Ltd., UK
SOURCE: Brit., 7 pp.
CODEN: BRXXAA
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1552126	A	19790905	GB 1975-24949	19760629
PRIORITY APPLN. INFO.:			GB 1975-24949 A	19760629

GI



I

AB The oxazole amines I (R, R1 = C1-6 alkyl, C2-6 alkenyl, C3-6 alkynyl, C2-6 alkoxyalkyl, C2-6 carboxyalkyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-6 alkyl, optionally substituted Ph, phenylalkyl, or phenylalkenyl; NRR1 = 5-7-membered heterocycle; the oxazole ring is optionally further substituted) were prepared I are useful (no data) in the treatment of immediate hypersensitivity diseases including asthma and in the alleviation of status asthmaticus; they have low toxicity. Thus, 2-(N-butyl-N-isobutyl)amino-4-methyloxazole was prepared from 2-butylamino-4-methyloxazole by treatment in DMF with NaH (0°, 0.5 h) and Me2CHCH2I (room temperature, 11 h).

IT **73801-94-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as allergy and asthma inhibitor)

RN 73801-94-2 CAPLUS
CN 2-Oxazolamine, N,N-dibutyl-4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 183 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1977:189775 CAPLUS
DOCUMENT NUMBER: 86:189775
TITLE: Photorearrangements of phenyloxazoles
AUTHOR(S): Maeda, Minoru; Kojima, Masaharu
CORPORATE SOURCE: Fac. Pharm. Sci., Kyushu Univ., Fukuoka, Japan
SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1977), (3), 239-47
CODEN: JCPRB4; ISSN: 0300-922X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 86:189775
GI



II

AB Phenyloxazoles underwent two photo rearangements; formal interchange of positions 2 and 3 or 4 and 5, which is rationalized in terms of a ring-contraction-ring expansion sequence, and interchange of positions 2 and 4 or 3 and 5 which involves a bicyclic intermediate. E.g., irradiation of 2,5-diphenyloxazole in EtOH gave 3% 3,5-diphenylisoxazole and 20% 4,5-diphenyloxazole. Irradiation of 2-phenyloxazole (I) in C6H6 or cyclohexane gave the azirinecarboxaldehyde II and 4-phenyloxazole. The correlation between photolysis of I and its electronic structure, as deduced from semiempirical SCF-MO and SCF-CI calcns., is discussed.

IT **62921-40-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and photolysis of)

RN 62921-40-8 CAPLUS
CN Oxazole, 4-(4-methoxyphenyl)-5-phenyl- (9CI) (CA INDEX NAME)



L10 ANSWER 10 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:960190 CAPLUS
DOCUMENT NUMBER: 124:8796
TITLE: Preparation of 4,5-diaryloxazole derivatives as PGI2 agonists
INVENTOR(S): Taniguchi, Kiyoshi; Nagano, Masanobu; Hattori, Kouji; Tsubaki, Kazunori; Okitsu, Osamu; Tabuchi, Seiichiro
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9517393	A1	19950629	WO 1994-JP2116	19941216
W: AU, CA, CN, HU, JP, KR, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2179399	AA	19950629	CA 1994-2179399	19941216
AU 9512006	A1	19950710	AU 1995-12006	19941216
AU 686286	B2	19980205		
EP 736018	A1	19961009	EP 1995-902969	19941216
EP 736018	B1	20000705		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1138328	A	19961218	CN 1994-194557	19941216
CN 1046714	B	19991124		
JP 09506894	T2	19970708	JP 1994-517312	19941216
HU 76341	A2	19970828	HU 1996-1685	19941216
AT 194335	E	20000715	AT 1995-902969	19941216
ES 2147836	T3	20001001	ES 1995-902969	19941216
PT 736018	T	20001031	PT 1995-902969	19941216
RU 2176640	C2	20011210	RU 1996-115170	19941216
US 6025375	A	20000215	US 1998-92027	19980605
CN 1229795	A	19990929	CN 1998-116704	19980725
CN 1090184	B	20020904		
GR 3034542	T3	20010131	GR 2000-402232	20001004

PRIORITY APPLN. INFO.:	GB 1993-25962	A	19931220
	GB 1994-22404	A	19941107
	WO 1994-JP2116	W	19941216

OTHER SOURCE(S): MARPAT 124:8796
GI



AB Title compds. [I; R = R1A1OZA2Z1; A1 = alkylene; A2 = bond, alkylene; R1 = (protected)CO2H; R2,R3 = (un)substituted aryl; Z = phenylene; Z1 = phenylene, cycloalk(en)ylene(methylene)] were prepared Thus, Et 5(R)-acetoxy-1-cyclopentenecarboxylate was alkylated by the Grignard reagent from 3-(MeO)C6H4CH2Cl and the saponified product esterified by benzoin to give, after cyclization with NH4OAc and 3 addnl. steps, title compound (S)-II (III; n = 0). III (N = 1) gave 31.3% decrease in blood pressure in rats at 3.2mg/kg orally.

IT **171045-85-5P 171045-86-6P 171045-89-9P**
171045-90-2P 171046-19-8P 171046-20-1P
171046-25-6P 171046-26-7P 171046-27-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4,5-diaryloxazole derivs. as PGI2 agonists)

RN 171045-85-5 CAPLUS

CN Acetic acid, [3-[[2-[4,5-bis(4-methylphenyl)-2-oxazolyl]-2-cyclohexen-1-yl]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 171045-86-6 CAPLUS

CN Acetic acid, [3-[[2-[4,5-bis(4-methylphenyl)-2-oxazolyl]-2-cyclopenten-1-yl]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 171045-89-9 CAPLUS
CN Acetic acid, [3-[[2-[4,5-bis(4-methylphenyl)-2-oxazolyl]cyclohexyl]methyl]phenoxy]-, ethyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 171045-90-2 CAPLUS
CN Acetic acid, [3-[[2-[4,5-bis(4-methylphenyl)-2-oxazolyl]cyclohexyl]methyl]phenoxy]-, ethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 171046-19-8 CAPLUS
CN Acetic acid, [3-[[2-[4,5-bis(4-methylphenyl)-2-oxazolyl]-2-cyclohexen-1-yl]methyl]phenoxy]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 171046-20-1 CAPLUS
CN Acetic acid, [3-[[2-[4,5-bis(4-methylphenyl)-2-oxazolyl]-2-cyclopenten-1-yl]methyl]phenoxy]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 171046-25-6 CAPLUS
CN Acetic acid, [3-[[2-[4,5-bis(4-methylphenyl)-2-oxazolyl]cyclohexyl]methyl]phenoxy]-, sodium salt, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 171046-26-7 CAPLUS
CN Acetic acid, [3-[[2-[4,5-bis(4-methylphenyl)-2-oxazolyl]cyclohexyl]methyl]phenoxy]-, sodium salt, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Na

RN 171046-27-8 CAPLUS
CN Acetic acid, [3-[[2-[4,5-bis(4-methylphenyl)-2-oxazolyl]cyclohexyl]methyl]phenoxy]-, sodium salt (9CI) (CA INDEX NAME)



● Na

IT **171046-56-3P 171046-68-7P 171046-69-8P**
171046-70-1P 171046-71-2P 171046-81-4P
171046-82-5P 171046-83-6P 171047-02-2P,
4,5-Bis(4-methylphenyl)oxazole
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4,5-diaryloxazole derivs. as PGI2 agonists)

RN 171046-56-3 CAPLUS
CN Oxazole, 2-[2-[(3-methoxyphenyl)methyl]cyclohexyl]-4,5-bis(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 171046-68-7 CAPLUS
CN Cyclopentanol, 1-[4,5-bis(4-methylphenyl)-2-oxazolyl]-2-[(3-methoxyphenyl)methyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 171046-69-8 CAPLUS
CN Cyclopentanol, 1-[4,5-bis(4-methylphenyl)-2-oxazolyl]-2-[(3-methoxyphenyl)methyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 171046-70-1 CAPLUS
CN Cyclohexanol, 1-[4,5-bis(4-methylphenyl)-2-oxazolyl]-2-[(3-methoxyphenyl)methyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 171046-71-2 CAPLUS
CN Cyclohexanol, 1-[4,5-bis(4-methylphenyl)-2-oxazolyl]-2-[(3-methoxyphenyl)methyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 171046-81-4 CAPLUS
CN Phenol, 3-[[2-[4,5-bis(4-methylphenyl)-2-oxazolyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)



RN 171046-82-5 CAPLUS
CN Phenol, 3-[[2-[4,5-bis(4-methylphenyl)-2-oxazolyl]-2-cyclohexen-1-

yl]methyl]- (9CI) (CA INDEX NAME)



RN 171046-83-6 CAPLUS
CN Phenol, 3-[[2-[4,5-bis(4-methylphenyl)-2-oxazolyl]-2-cyclopenten-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 171047-02-2 CAPLUS
CN Oxazole, 4,5-bis(4-methylphenyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 40 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1971:510311 CAPLUS
DOCUMENT NUMBER: 75:110311
TITLE: Analgesic, antiinflammatory, and antipyretic imidazole derivatives
INVENTOR(S): Fitzi, Konrad; Pfister, Rudolf
PATENT ASSIGNEE(S): CIBA-Geigy A.-G.
SOURCE: Ger. Offen., 65 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2064520	A	19710708	DE 1970-2064520	19701230
DE 2064520	C3	19800522		
DE 2064520	B2	19790830		
CH 523257	A	19720531	CH 1969-523257	19691231
GB 1328550	A	19730830	GB 1970-59838	19701217
NL 7018745	A	19710702	NL 1970-18745	19701223
NL 167691	B	19810817		
NL 167691	C	19820118		
NO 129574	B	19740429	NO 1970-4949	19701223
SE 368574	B	19740708	SE 1970-17498	19701223
DK 129346	B	19740930	DK 1970-6554	19701223
ZA 7008741	A	19711027	ZA 1970-8741	19701230
FR 2081407	A1	19711203	FR 1970-47251	19701230
FR 2081407	A5	19711203		
IL 35935	A1	19741129	IL 1970-35935	19701230
CA 960679	A1	19750107	CA 1970-101707	19701230
JP 51023506	B4	19760717	JP 1970-123140	19701230

PRIORITY APPLN. INFO.: CH 1969-19401 A 19691231
GI For diagram(s), see printed CA Issue.
AB I was prepared (A) by condensing a substituted benzil with excess NH3 [and (or) DMF] and an aldehyde; (B) by oxidation of a substituted benzoin with Cu2+; (C) by refluxing an amide with AcOH or HCO2H; (D) by condensation of an amidine with an ester of a substituted benzoin; and (E) by heating an oxazole with liquid NH3 and HCONH2 to 180-220°. Approx. 36 I were prepared
IT **33420-71-2P 33420-72-3P 33420-73-4P**
33420-74-5P 33425-71-7P 33512-72-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 33420-71-2 CAPLUS
CN Oxazole, 4,5-bis(4-methoxyphenyl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 33420-72-3 CAPLUS
CN Oxazole, 2-cyclopropyl-4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 33420-73-4 CAPLUS
CN Oxazole, 4-(4-methoxyphenyl)-2-(1-methylethyl)-5-phenyl- (9CI) (CA INDEX NAME)



RN 33420-74-5 CAPLUS
CN Oxazole, 2-(1,1-dimethylethyl)-4,5-bis(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 33425-71-7 CAPLUS
CN Oxazole, 2-(1,1-dimethylethyl)-4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 33512-72-0 CAPLUS
CN Oxazole, 2-ethyl-4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 48 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1984:185259 CAPLUS
DOCUMENT NUMBER: 100:185259
TITLE: Metabolic fate of oxaprozin. 3. Metabolism of 14C-oxaprozin
AUTHOR(S): Suwa, Toshio; Urano, Hidetoshi; Minagawa, Toshiya; Tsubokawa, Mieko; Kyogoku, Kazuaki
CORPORATE SOURCE: Res. Cent., Taisho Pharm. Co., Ltd., Omiya, 330, Japan
SOURCE: Oyo Yakuri (1984), 27(1), 147-55
CODEN: OYYAA2; ISSN: 0369-8033
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
GI



I

AB Following oral administration (50 mg/kg), oxaprozin (I) [21256-18-8] appeared mainly in unchanged form in the plasma of dogs, mice, and rabbits, but appreciable amts. of Ph-monohydroxylated metabolites were observed in rat plasma. Pharmacokinetic studies showed plasma half-lifes of 2-5 h in rats, rabbits, and mice and .apprx.52 h in dogs. Metabolites were isolated from the excreta by chromatog. and identified by their mass spectra, NMR spectra, and comparison with authentic samples. In dogs, the principal metabolite was I glucuronide, whereas in mice and rabbits, the monohydroxylated metabolites were identified as the major metabolites in the urine and feces. In rats, I was completely metabolized, and many metabolites, including mono- and dihydroxylalated and methoxylated-hydroxylated compds., were found in the urine, bile, and feces as free or conjugated forms.

IT **68192-19-8 90044-49-8 90044-50-1 90044-51-2 90044-52-3**
RL: FORM (Formation, nonpreparative)
(formation of, as oxaprozin metabolite)

RN 68192-19-8 CAPLUS
CN 2-Oxazolepropanoic acid, 4-(4-hydroxyphenyl)-5-phenyl- (9CI) (CA INDEX NAME)



RN 90044-49-8 CAPLUS
CN 2-Oxazolepropanoic acid, 5-(4-hydroxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 90044-50-1 CAPLUS
CN 2-Oxazolepropanoic acid, 4-(3-hydroxyphenyl)-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 90044-51-2 CAPLUS
CN 2-Oxazolepropanoic acid, 5-(3,4-dihydroxy-1,5-cyclohexadien-1-yl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 90044-52-3 CAPLUS
CN 2-Oxazolepropanoic acid, 4-(3,4-dihydroxy-1,5-cyclohexadien-1-yl)-5-phenyl- (9CI) (CA INDEX NAME)


OH
OH
HO2C— CH2— CH2
N
O
Ph

L10 ANSWER 61 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1987:477782 CAPLUS
DOCUMENT NUMBER: 107:77782
TITLE: 4-(4-Hydroxyphenyl)-5-phenyl-2-oxazolepropanoic acid and 5-(4-hydroxyphenyl)-4-phenyl-2-oxazolepropanoic acid as inflammation inhibitors
INVENTOR(S): Lewis, Alan J.; Carlson, Richard P.; Fletcher, Horace, III
PATENT ASSIGNEE(S): American Home Products Corp., USA
SOURCE: U.S., 4 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4659728	A	19870421	US 1985-704824	19850225
PRIORITY APPLN. INFO.:			US 1985-704824	19850225

AB The title compds. are antiinflammatories prepared by cyclocondensation of methoxybenzoins with succinic anhydride and NH4OAc followed by ether cleavage. 4-Methoxybenzoin was heated with succinic anhydride and Et3N in PhMe for 3 h, cooled, and HOAc/NH4OAC were added to the reaction. mixture, which was heated to reflux with removal of solvent by distillation to give 4-(4-hydroxyphenyl)-5-phenyl-2-oxazolepropanoic acid (I). In the rat paw edema test 150 mg I/kg gave 46% control of carrageenan-induced paw edema.

IT **24248-45-1P 109620-53-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and ether cleavage reaction of)

RN 24248-45-1 CAPLUS
CN 2-Oxazolepropanoic acid, 4-(4-methoxyphenyl)-5-phenyl- (9CI) (CA INDEX NAME)



RN 109620-53-3 CAPLUS
CN 2-Oxazolepropanoic acid, 5-(4-methoxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)



IT **68192-19-8P 90044-49-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as inflammation inhibitor)
RN 68192-19-8 CAPLUS
CN 2-Oxazolepropanoic acid, 4-(4-hydroxyphenyl)-5-phenyl- (9CI) (CA INDEX NAME)



RN 90044-49-8 CAPLUS
CN 2-Oxazolepropanoic acid, 5-(4-hydroxyphenyl)-4-phenyl- (9CI) (CA INDEX NAME)



L10 ANSWER 82 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1953:65369 CAPLUS
DOCUMENT NUMBER: 47:65369
ORIGINAL REFERENCE NO.: 47:11053e-f
TITLE: Oxazole cyanine and merocyanine dyes, and intermediates
AUTHOR(S): Jeffreys, R. A.
CORPORATE SOURCE: Natl. Inst. for Med. Research, London
SOURCE: Journal of the Chemical Society, Abstracts (1952) 4823-32
CODEN: JCSAAZ; ISSN: 0590-9791
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB A direct synthesis of 2-methyl-4(or 4,5-di)-substituted oxazoles from phenacyl bromides and NH4OAc has been achieved. The synthesis of Japp, et al., (J. Chemical Society 63, 469(1893)) and Davidson, et al., (C.A. 32, 1702.8) has been extended to 4,5-dialkyl- and 4-aryloxazoles, resp. These together with 2-methyloxazole have been quaternized and converted into cyanine and merocyanine dyes. A comparison of the dye absorption maximum throws some light upon the spacial configuration of the 4- and 5-aryl substituents in the oxazole nucleus. In the synthesis of diaryloxazoles, prolonging the reaction period slowly converts the oxazoles into the corresponding glyoxalines.

IT **797802-42-7**, Oxazole, 4-(3,4-dimethoxyphenyl)-2-methyl-5-phenyl-
797802-61-0, Oxazole, 4-(3,4-dimethoxyphenyl)-2-methyl-5-phenyl-, hydrochloride **855404-92-1**, Oxazole, 4-(p-methoxyphenyl)-2-methyl-5-phenyl-
(preparation of)

RN 797802-42-7 CAPLUS
CN Oxazole, 4-(3,4-dimethoxyphenyl)-2-methyl-5-phenyl- (5CI) (CA INDEX NAME)



RN 797802-61-0 CAPLUS
CN Oxazole, 4-(3,4-dimethoxyphenyl)-2-methyl-5-phenyl-, hydrochloride (5CI) (CA INDEX NAME)



● HCl

RN 855404-92-1 CAPLUS
CN Oxazole, 4-(p-methoxyphenyl)-2-methyl-5-phenyl- (5CI) (CA INDEX NAME)



L10 ANSWER 106 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1982:406298 CAPLUS
DOCUMENT NUMBER: 97:6298
TITLE: Trisubstituted imidazole derivatives: pharmaceutical compositions containing them and their use
INVENTOR(S): Sallmann, Alfred
PATENT ASSIGNEE(S): Ciba-Geigy A.-G. , Switz.
SOURCE: Eur. Pat. Appl., 108 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 45081	A2	19820203	EP 1981-105914	19810727
EP 45081	A3	19820407		
EP 45081	B1	19860108		
R: AT, BE, CH, DE, FR, IT, LU, NL, SE				
DD 201677	A5	19830803	DD 1981-232030	19810723
CA 1175431	A1	19841002	CA 1981-382377	19810723
DK 8103318	A	19820126	DK 1981-3318	19810724
FI 8102326	A	19820126	FI 1981-2326	19810724
NO 8102542	A	19820126	NO 1981-2542	19810724
AU 8173404	A1	19820128	AU 1981-73404	19810724
GB 2080805	A	19820210	GB 1981-22920	19810724
GB 2080805	B2	19840307		
ZA 8105078	A	19820728	ZA 1981-5078	19810724
ES 504257	A1	19821201	ES 1981-504257	19810724
HU 27879	O	19831128	HU 1981-2178	19810724
HU 188069	B	19860328		
IL 63410	A1	19860429	IL 1981-63410	19810724
IL 72665	A1	19860429	IL 1981-72665	19810724
SU 1235454	A3	19860530	SU 1981-3317053	19810724
JP 57056466	A2	19820405	JP 1981-115896	19810725
PL 135822	B1	19851231	PL 1981-232352	19810725
AT 17349	E	19860115	AT 1981-105914	19810727
SU 1138023	A3	19850130	SU 1982-3465351	19820721
SU 1145928	A3	19850315	SU 1982-3466066	19820721
SU 1205764	A3	19860115	SU 1982-3465356	19820721
SU 1227112	A3	19860423	SU 1982-3466067	19820721
ES 514579	A1	19830516	ES 1982-514579	19820730
ES 514580	A1	19830516	ES 1982-514580	19820730
ES 514581	A1	19830516	ES 1982-514581	19820730
ES 514582	A1	19830516	ES 1982-514582	19820730
ES 514583	A1	19830516	ES 1982-514583	19820730
ES 514584	A1	19830516	ES 1982-514584	19820730
ES 514585	A1	19830701	ES 1982-514585	19820730
DD 202554	A5	19830921	DD 1982-242110	19820730
SU 1152520	A3	19850423	SU 1982-3469534	19820730
SU 1169534	A3	19850723	SU 1982-3468675	19820730
US 4447431	A	19840508	US 1982-425603	19820928
SU 1205763	A3	19860115	SU 1983-3618708	19830719
CA 1185976	A2	19850423	CA 1984-451683	19840410
AU 8656555	A1	19860911	AU 1986-56555	19860423
PRIORITY APPLN. INFO.:			CH 1980-5715 A	19800725
			US 1981-285231 A3	19810720

CA 1981-382377 A3 19810723
IL 1981-63410 A 19810724
EP 1981-105914 A 19810727

GI



I



II

AB Imidazoles I (R1, R2 = carbocyclic aryl, heteroaryl; R3 = CO2H, esterified or amidated CO2H; Z = hydrocarbondiyl), and their isomers and salts, useful as inflammation inhibitors, virucides, and sunscreens and in treatment against Herpes virus (no data), were prepared Refluxing 1-phenyl-2-(3-pyridyl)glyoxal, Me2C(CHO)CO2Et, NH4OAc, and AcOH 1 h and pouring the mixture into ice-concentrated aqueous NH3 gave II.

IT **81891-71-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and amidation of)

RN 81891-71-6 CAPLUS

CN 2-Oxazoleacetic acid, 4,5-bis(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



IT **81891-72-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 81891-72-7 CAPLUS

CN 2-Oxazoleacetamide, 4,5-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


O
H2N
C
CH2
N
O
OMe
OMe

L10 ANSWER 117 OF 195 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:772452 CAPLUS
DOCUMENT NUMBER: 143:7629
TITLE: New aspects of solid-phase organic synthesis: ring formation reactions using active species on a solid support and efficient construction of heterocyclic compound libraries
AUTHOR(S): Iso, Yasuyoshi
CORPORATE SOURCE: Shionogi Research Laboratories, Shionogi & Co., Ltd., Fukushima-ku, Osaka, 553-0002, Japan
SOURCE: Trends in Heterocyclic Chemistry (2003), 9, 61-68
CODEN: TIHCE6
PUBLISHER: Research Trends
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A simple and efficient method for preparing α-TMSdiazoketones, as a source of carbenes or carbenoids, from carboxylic acid derivs. on a solid support, is employed to perform a variety of solid-phase reactions. Resin-bound α-TMSdiazoketones having diverse substrates were successfully used in a variety of solid-phase reactions including ring formation reactions, such as oxazole synthesis, and fused ring formation by intramol. Buchner reaction, via carbenoids. The use of these solid-phase reactions with combinatorial chemical should contribute greatly to efficient construction of heterocyclic compound libraries to search for interesting compds. for new drugs.

IT **299409-25-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(solid phase preparation of oxazoles via reaction of aryl nitriles with solid supported α-TMS-diazoketones)
RN 299409-25-9 CAPLUS
CN Phenol, 4-[4-(4-methylphenyl)-2-phenyl-5-oxazolyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT